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Abstract
Purpose: To study the effect of resveratrol, a putative chemopreventive
phytoalexin, on DNA synthesis, cell cycle, apoptosis, and the possible invol-
vement of the transcription factor NF-κB.
Methods: HL-60, a suspension human promyelocytic leukemia cell line,
and HepG2, an epithelial human hepatoma-derived cell line were chosen as
models. Incorporation of 3H-labelled thymidine and cell cycle distribution,
assessed by binding of Propidium Iodine and flow cytometry, were used to
evaluate the effect on cell proliferation. The effect on apoptosis was studied by
the use of several assays. The nuclei were stained with DAPI and subsequent-
ly visualised with fluorescence microscopy. Bound Annexin-V and activity of
Caspase-8 were evaluated by flow cytometry. Cleavage of Caspase-3 was asses-
sed by Western blot. The effect of resveratrol on NF-κB transactivating acti-
vity was studied by a reporter gene assay. Phosphorylation of the RelA/p65
NF-κB subunit was evaluated by Western blot. Levels of resveratrol were eva-
luated by light-absorption, and size of isolated cell nuclei was assessed by flow
cytometry.
Results: Resveratrol induces a complex dose and time dependent re-
duction in incorporation of 3H-labelled thymidine. The IC50 value increased
with increase in incubation time and short term treatment had an inhibitory
effect on the incorporation of thymidine. These effects are previously unrepor-
ted for the used cell lines. It was observed for the first time that when in FCS
containing solution, levels of resveratrol decreased. It was found that resve-
ratrol induced a dose dependent accumulation in the S and G1 phases of the
cell cycle in both cell lines. In addition, an enlargement of the HL-60 but not
HepG2 nuclei was observed. The nuclear enlarging effect is previously unrepor-
ted. Resveratrol was found to stimulate apoptosis in a dose dependent manner
in HL-60 cells. Caspase-3 and Caspase-8 were furthermore found to be activa-
ted. Basal and TNF-α stimulated NF-κB activity was found to be inhibited by
resveratrol in a dose dependent manner. HL-60 cells were furthermore found
not to be suitable for studying phosphorylation of RelA/p65.
Conclusion: Resveratrol modulates the cell cycle in a complex fashion.
Apoptosis is stimulated in a dose dependent manner, with activation of the
extrinsic and the intrinsic pathways. The involvement of NF-κB in the observed
cellular effects remains unclear.
i
Resume´
Form˚al: At undersøge effekterne af resveratrol, et formodet chemopræ-
ventivt phytoalexin, med hensyn til DNA syntese, cellecyclus og apoptose.
Transskriptionsfaktoren NF-κB blev ogs˚a undersøgt, med henblik p˚a en mulig
rolle i observerede cellulære effekter.
Metoder: HL-60, en human promyelocytisk leukæmi suspensionscellelinie
og HepG2, en human epitel hepatoma-afledt cellelinie blev valgt som modeller.
Inkorporeringen af 3H-mærket thymidin og cellecyklusfordeling, undersøgt ved
binding af Propidium Iodid og flowcytometri, blev anvendt til at studere ef-
fekten p˚a celleproliferation. Apoptosestimulerende effekter blev undersøgt ved
flere assays: Farvning af kerner med DAPI og efterfølgende visualisering ved
fluorescensmikroskopi. Mængden af bundet Annexin-V og Caspase-8 aktivitet
blev undersøgt ved flowcytometri, mens kløvning af Caspase-3 blev undersøgt
ved Western blot. Effekter p˚a transaktivering af NF-κB blev undersøgt ved et
reportergenassay, mens fosforylering af NF-κB subuniten RelA/p65 blev un-
dersøgt ved Western blot. Mængden af resveratrol blev undersøgt ved lysab-
sorption, og størrelsen af isolerede cellekerner blev bestemt ved flowcytometri.
Resultater: Resveratrol inducerede en kompliceret dosis- og tids-
afhængig reduktion i inkorporeringen af 3H-mærket thymidin. Det blev
observeret, at IC50-værdien steg med inkubationstiden, og at korttidsbehand-
ling havde en hæmmende effekt p˚a inkorporeringen af thymidin. Disse effekter
er ikke tidligere observeres i de anvendte cellelinier. For første gang blev det
observeret, at niveauet af resveratrol i en FCS-holdig opløsning, mindskedes.
B˚ade HL-60 og HepG2 celler s˚as ophobet i S eller G1 fasen af cellecyklus,
afhængig af den anvendte resveratrol koncentration. Derudover blev størrelsen
af HL-60 cellekernerne fundet forøget, en effekt, der ikke tidligere er rapporte-
ret. Resveratrol stimulerede dosisafhængig apoptose i HL-60 celler. Ydermere
blev Caspase-3 og Caspase-8 aktiveret. En dosisafhængig reduktion i basal
og TNF-α stimuleret NF-κB aktivitet lod sig observere. Slutteligt vurderedes
HL-60 at være mindre velegnede til studier af fosforylering af RelA/p65.
Konklusion: Resveratrol modulerer cellecyklus p˚a kompliceret vis. Apop-
tose stimuleres dosisafhængigt og inkluderer aktivering af den receptormedi-
erede og den mitokondrielle pathway. Involveringen af NF-κB i de cellulære
effekter er uafklaret.
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Introduction
Cancer is one of the leading causes of death in the Western world. It is
known that the risk of developing the disease can be greatly reduced by a
change of lifestyle and, importantly, a change of dietary habits. Many plant-
based foods with putative anti-cancer effects, such as garlic, soy beans, ginger,
onions, tomatoes, and the cruciferous greens (e.g. broccoli and cabbage) have
been identified. In these fruits and vegetables more than 400 compounds are
currently under investigation for their health promoting properties.
Resveratrol One of these many compounds is resveratrol, a phytoalexin
found in grapes, red wine, and peanuts. The interest in the health promoting
properties of resveratrol was sparked when it was originally discovered in red
wine, and thus identified as a possible key player in so called“French Paradox”.
This phrase was coined to explain the lower number of cases of coronary heart
disease in various parts of France, compared to other industrialised countries,
despite a high consumption of dietary fats.
A discussion of the “French Paradox” is beyond the scope of this report.
For a comprehensive review see Goldberg et al. (1995a). The health promoting
properties of wine over other alcoholic beverages is not yet consolidated, and
was recently discussed in Grønbæk (2004); Li and Mukamal (2004).
Since the discovery of resveratrol as an inhibitor of tumorigenesis in 1997
(Jang et al., 1997), the compound has experienced an increasing attention
from the scientific community. Resveratrol has been shown not only to inhibit
cancer initiation, but also reverse development of growths in several different
types of cancers. However, the mechanism by which resveratrol exerts the
health promoting effects is not yet fully elucidated.
Mechanisms regulating cell division and cell death may be affected by
phytochemicals. The transcription factor NF-κB is central in controlling the
expression of a range og genes, whose products are involved in cell cycle and
apoptosis. In the present work, the effects of resveratrol on DNA synthesis
and cell cycle, as well as apoptosis in HL-60 ans HepG2 cells will be discussed.
Furthermore, the role of NF-κB as a possible mediator will be evaluated.
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Nomenclature The nomenclature used in this report is based on the sug-
gestions for gene nomenclature set forth by the Human Gene Nomenclature
Committee (Wain et al., 2002, and later post-publication on-line updates1)
and the Nomenclature Committee of the International Union of Biochemistry
and Molecular Biology2 where applicable. This attempt to adhere to standards
will result in rather uncommon names for most of the factors described. In
order to alleviate the transition from the somewhat anarchistic nomenclature
used in most of the literature to the more standardised nomenclature, the “old
name” will be mentioned together with the recommended abbreviation.
1http://www.gene.ucl.ac.uk/nomenclature/guidelines.html
2http://www.chem.qmul.ac.uk/iupac/jcbn/
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Abbreviations used
BaP Benzo[a]pyrene
BSA Bovine serum albumin
Caspase Cysteine-aspartic-acid-protease – all variants
Cdk Cyclin-dependent kinase – all variants
CdkN Cyclin-dependent kinase inhibitor – all variants
DAPI 4’,6-Diamidino-2-phenylindole – a DNA binding fluorophor
DMBA 7,12-dimethylbenz[a]anthracene
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethylsulfoxide
EGFP Enhanced green fluorescent protein – a fluorophor
EMSA Electric mobility shift assay
FAM Carboxyfluorescein – a fluorophor
FCS Fetal calf serum
FL1-H Fluorescence intensity height, channel 1
FL2-H Fluorescence intensity height, channel 2
FL3-H Fluorescence intensity height, channel 3
FSC-H Forward scatter height – particle size
HPLC High performance liquid chromatography
IKBK/IKK NF-κB inhibitor kinase – all variants
IL-1β Interleukin 1, beta
LPS Lipopolysaccharide
MTT Tetrazolium salt –
3(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
NF-κB Nuclear factor κB – all variants
NF-κBi/IκB NF-κB inhibitor – all variants
NR Neutral Red
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ODC Ornithine Decarboxylase
PBS Phosphate buffered saline
PI Propidium Iodine – a DNA/RNA binding fluorophor
PS Phosphatidylserine
RB1 Retinoblastoma protein
RHD Rel homology domain
RLU Relative luminescence unit
SD Standard deviation
SSC-H Side scatter height – particle granularity
TNF-α Tumor necrosis factor
TNFRSF Tumor necrosis factor receptor superfamily
TPA 12-O-tetradecanoylphorbol-13-acetate – also known as
Phorbol-12-myristate-13-acetate (PMA)
UV Ultraviolet
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Chapter 1
Background
This chapter reviews the current status of research on selected cellular effects
of resveratrol. The studies presented in this report comprise the effect of
resveratrol on cell growth, cell cycle progression, apoptosis, and the possible
involvement of NF-κB. The purpose of this review is to give the reader the
required background to interpret the presented data and follow the discussion
in the succeeding two chapters.
The chapter starts with a general introduction to resveratrol and the pu-
tative beneficial effects of the compound. After a brief introduction to the ele-
ments of the eukaryotic cell cycle, the cell cycle modulating effects of resvera-
trol is reviewed. Mechanisms of apoptosis and the specific effects of resvera-
trol on apoptosis are subsequently discussed. Finally, current knowledge on
the NF-κB signal transduction system and the effect of resveratrol on NF-κB
activity is described.
1.1 Resveratrol
Resveratrol is a phytochemical present in a variety of plant species, some of
which are used for human consumption, e.g. peanuts, eucalyptus, blueber-
ries, cranberries, and grapes. It is also found in the roots of Japanese knot-
weed (Polygonum cuspidatum), which has been used in traditional Asian herb
medicine to reduce inflammation. While the levels of resveratrol are highest
in the latter, grapes are probably the most important source of resveratrol for
humans, since the compound is also found in one of end product of grapes i.e
wine. (reviewed in Aggarwal et al., 2004; Bhat and Pezzuto, 2002; Sobolev
and Cole, 1999; Soleas et al., 1997)
Following it’s discovery as a phytoalexin in grapes in 1976 by Langcake
and Pryce and later in wine (Siemann and Creasy, 1992), resveratrol has en-
joyed a growing scientific interest over the years. This interest is mainly due to
multiple lines of evidence from in vitro and in vivo studies suggesting cancer
preventive properties (Aggarwal et al., 2004; Jang et al., 1997), as well as epi-
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Figure 1.1: Chemical structures of resveratrol.
demiological studies indicating an inverse relationship between moderate red
wine consumption and coronary heart disease, the so called “French Paradox”
(reviewed in Kundu and Surh, 2004; Sun et al., 2002).
The mechanisms behind these effects of resveratrol are not fully elucidated,
but the compound has been demonstrated to include 1) anti-oxidant activity,
by scavenging and/or regulation of synthesis of scavenging proteins 2) inhibi-
tion of carcinogen activation 3) increase carcinogen detoxification 4) inhibition
of inflammation 5) modulation of cell cycle progression 6) stimulation of apop-
tosis (Cao et al., 2003; Dong, 2003; Greten et al., 2004; Kundu and Surh, 2004;
Surh, 2003).
However, resveratrol may also have a cancer initiating effect, as genotoxi-
city has been reported (Ahmad et al., 2000; Matsuoka et al., 2001, 2002).
1.1.1 Physical properties of resveratrol
Structure Resveratrol (3,5,4’-Trihydroxystilbene) is a polyphenol composed
of two phenol rings connected by a double bond (figure 1.1). It exists in two
isoforms; trans-resveratrol and cis-resveratrol where the trans-isomer is the
more stable form (Trela and Waterhouse, 1996). The trans to cis isomerisation
is facilitated by ultraviolet light and high pH, while cis to trans isomerisation
is facilitated by visible light, high temperature, or low pH (Goldberg et al.,
1995b; Trela and Waterhouse, 1996). However, when kept in the dark at
room temperature cis-resveratrol is stable for at least a month (Trela and
Waterhouse, 1996).
Physical properties Pure resveratrol is an off-white powder with a molec-
ular mass of 228.24 g/mol. It is hydrophobic but dissolves in ethanol and
Dimethylsulfoxide (DMSO). The absorption maxima is approximately 286 nm
for cis-resveratrol, and 308 nm for trans-resveratrol. The different absorp-
tion maxima makes high performance liquid chromatography (HPLC) with
ultraviolet (UV) detection possible (Deak and Falk, 2002; Goldberg et al.,
1995b; Lamuela-Raventos et al., 1995; Trela and Waterhouse, 1996). Other
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used means of detecting cis- and trans-resveratrol are liquid chromatography
and gas chromatography (Soleas et al., 1997; Vin˜as et al., 2000).
Throughout the present report resveratrol refers to trans-resveratrol unless
otherwise specified.
Biosynthesis In grapes, the phytoalexin resveratrol is synthesized almost
entirely in the skin, and the synthethetic potential of grapes is highest just
before they reach maturity. The terminal enzyme in the biosynthesis of resver-
atrol is stilbene synthase, which is activated in response to exogenous stress
factors, such as injury, UV irradiation and chemical signals from pathogen
fungi. The levels of resveratrol are highest almost immediately after stress
exposure, and decline after 42-72 h as result of activation of stilbene oxidase.
(reviewed in Pervaiz, 2003; Soleas et al., 1997). A recent report suggested that
postharvest UV irradiation can be used to produce grapes with a very high
content of resveratrol (Cantos et al., 2001).
Levels of resveratrol in red wine The average levels of trans-resveratrol
in red wine is often cited as being 5 mg/l. However, the average levels varies
greatly from country to country (table 1.1). Since resveratrol is produced by
the grape in response to exogenous stress factors, a regional difference is to be
expected (Goldberg et al., 1995b, 1996), as well as a difference from vintage
to vintage (Goldberg et al., 1996; Mart´ınez-Ortega et al., 2000). The average
red wine is estimated to contain approximately 2 mg/l resveratrol. The lowest
reported level of resveratrol was barely detectable in a Portuguese red wine
made from the Cabernet Sauvignon variety from 1988 (Mart´ınez-Ortega et al.,
2000). A Bordeaux, 1991 red wine (variety unknown) has the highest reported
levels of trans-resveratrol of 7.6 mg/l (Goldberg et al., 1995b). Using the wine
making technique of double maceration, levels as high as 18.9 mg/l has been
reported in Portuguese red wine (Alonso et al., 2002, vintage not presented).
1.2 Bioavailability and toxicity of resveratrol
Animal studies Using an isolated rat small intestine perfused with resver-
atrol, it was found that approximately 20 % of availible resveratrol was ab-
sorbed. The phytoalexin was mainly absorbed as resveratrol glucuronide and
only low levels of unconjugated resveratrol and resveratrol sulfate could be
found (Andlauer et al., 2000). In a similar set-up, 6 % of available resveratrol
was absorbed in jejunum (middle part of small intestine), and only as resver-
atrol glucuronide. The level of absorption in the ileum (lower part of small
intestine) was too low to quantify (Kuhnle et al., 2000). By determining the
levels of radioactivity in stool fractions (colon plus colon content plus feces)
and urine from rats collected over 24 h, as much as 50 to 80 % or radioactive
labelled reaveratrol is absorbed (Soleas et al., 2001). Taken together these
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Table 1.1: Average trans-resveratrol concentration in red wine.
The mean values are calculated on basis of levels of trans-resveratrol given
by the cited references. n is the number of wines studied. An average red
wine is estimated to contain 2 mg/l resveratrol
trans-resveratrol (mg/l)
Country Mean High Low Vintage n Reference
Australia 2.4 2.6 2.3 1991-1993 2 Goldberg et al. (1996)
Canada 3.5 5.6 1.2 1991-1992 2 Goldberg et al. (1995b)
2.3 – – 1995-1996 8 Faustino et al. (2003)
Chile 1.2 1.6 0.8 1990-1992 2 Goldberg et al. (1995b)
2.3 – – 1995-1998 10 Faustino et al. (2003)
France 1.6 2.9 0.6 – 5 Careri et al. (2003)
2.2 4.7 0.3 1988-1993 10 Goldberg et al. (1996)
3.6 7.6 1.4 1990-1993 6 Goldberg et al. (1995b)
3 6.8 0.6 1996-1997 7 de Lima et al. (1999)
Greece 1.1 2.5 0.5 1997 29 Kallithraka et al. (2001)
Italy 1.2 3.2 0.7 – 7 Wang et al. (2002b)
3.7 7.2 1.2 1988 - 1991 15 Mattivi (1993)
1.2 1.3 1.17 1990-1991 2 Goldberg et al. (1996)
Japan 1 2.3 0.1 – 22 Sato et al. (1997)
Portugal 1 5.7 n.d.a 1994-1997 34 de Lima et al. (1999)
Spain 1.6 2.1 1.1 1991 2 Goldberg et al. (1995b)
0.3 1.3 n.d. – 5 Lo´pez et al. (2001)
0.1 0.2 n.d. 1986-1996 14 Mart´ınez-Ortega et al. (2000)
1.9b 5.1 0.1 1995-2002 45 Moreno-Labanda et al. (2004)
Spain/Portugalc 3.5 5.9 2 – 8 Alonso et al. (2002)
USA 0.9 2.2 0.3 1990-1991 4 Goldberg et al. (1996)
0.9 1.7 0.3 1991-1992 4 Goldberg et al. (1995b)
1 – – 1994-1998 7 Faustino et al. (2003)
aNot detected; bDifferent wine making methods; cNo distinction made
findings indicates that resveratrol is absorbed in mainly duodenum (the upper
part of small intestine), and to a lesser extend in jejunum, while no absorption
takes place in ileum. Also the time course of residence of resveratrol in the
small intestine may have an influence on the total absorption of resveratrol.
Organ distribution In mice, following administion of 5 mg/kg radioac-
tive labelled resveratrol through an intra gastric tube (Vitrac et al., 2003),
relative high levels of radioactivity was found in duodenum after 1.5 h. The
levels stayed elevated until 6 h. Levels of radioactivity in the large intestine
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peaked after 3 h. In liver and kidney radioactivity was observed after 1.5 h
and the levels decreased after 6 h. Radioactivity of lung, spleen, heart, brain,
and testis was assessed only after 3 h, and radioactivity was found in all or-
gans. This is in concordance with observations made in gerbils given 30 mg/kg
intraperitoneally (Wang et al., 2002a). At 3 h only 27 % of the total radioac-
tivity of liver and kidney could be attributed to labelled trans-resveratrol, the
remaining 73 % radioactivity originated from conjugates.
In a similar set-up mice were administered 240 mg/kg resveratrol by gastric
intubation, the highest amounts of unmetabolised resveratrol was found in
plasma, liver, kidney, lung and heart after 15 min, and levels were undetectable
0 after 60 min as determined by HPLC (Sale et al., 2004). The kinetics of un-
metabolised resveratrol in plasma was similar to that observed in rats adminis-
tered 14 mg/kg by gavage (Soleas et al., 2001). In contrast to the observations
made by Vitrac et al. (2003) and Wang et al. (2002a), no significant levels of
resveratrol were detected in brain, small intestine or colonic mucosa by Sale
et al. (2004). The discrepancy may be explained by methodical differences.
Toxicity of resveratrol Juan et al. (2002) studied the harmful effects of
resveratrol on male Sprague-Dawley rats. Resveratrol was orally administered
as a daily dose of 20 mg/kg for 28 days. No difference in body weight nor
food and water intake was observed between the group receiving resveratrol
and the control group. This is in full concordance with other observations
(Bove et al., 2002; Caltagirone et al., 2000; Carbo´ et al., 1999; Hecht et al.,
1999; Kimura and Okuda, 2001; Tessitore et al., 2000; Ziegler et al., 2004).
Hematological and clinical biochemical parameters were not affected by the
treatment, with a rise in plasma levels of aspartate aminotransferase, as the
only exception. Aspartate aminotransferase is an indicator of liver injury
(Borini et al., 2003). Levels of the coronary heart disease indicators low density
lipoprotein and high density lipoprotein did not differ, in full agreement with
what has been reported by others (Wang et al., 2002c; Wilson et al., 1996).
No alterations were observed by a histopathological examination of the body
organs, including the liver. The relative weight of major organs did not differ
either, except for an increase in the relative weight of the brain and testes in
animals receiving resveratrol compared to the control group.
The dose used shows that with an arbitrary safety margin of 100 (human
versus rat), a person of 70 kg can consume at least 14 mg resveratrol daily,
without any side effects. This is equivalent to drinking 1.8 l Bordeaux, 1991
daily (Goldberg et al., 1995b). Taken together, the study by Juan et al.
(2002) indicates that there is a large safety margin regarding resveratrol to
repeated moderate wine consumption. However, due to the rise in plasma
levels of aspartate aminotransferase, resveratrol induced liver damage cannot
be excluded.
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Clinical trials In keeping with the findings from animal studies of high ab-
sorption of resveratrol, at least 70 % absorption of orally administered resver-
atrol (25 mg) was detected in a limited clinical trial (Walle et al., 2004). The
highest levels of resveratrol in plasma or serum were detected after 0.5 to 1 h,
in the range of 2 µM. However, resveratrol was mainly detected as sulfate
and glucuronide conjugates in plasma and serum, while levels of free trans-
resveratrol were negligible, in the range of 35 nM (Goldberg et al., 2003; Walle
et al., 2004).
Pharmacokinetics Walle et al. (2004) found that resveratrol and it’s
conjugates were lost mainly through urine in the course of 72 h with a half-life
of approximately 9 h (25 mg resveratrol was orally administered). Interest-
ingly, a rise in the total plasma levels of polyphenols, was observed in men
who consumed half a bottle of red wine (375 ml) daily for two weeks (Nigdikar
et al., 1998).
Metabolism of resveratrol Resveratrol is glucuronated in the human
liver and sulfated in both the liver as well as in the duodenum (Santi et al.,
2000a,b). The major conjugates are trans-resveratrol-3-O-glucuronide, trans-
resveratrol-4’-O-glucuronide, and trans-resveratrol-3-O-sulfate (Yu et al.,
2002). The kinetic data presented indicates glucuronation to prevail over
sulfation in the liver, and that the rate of sulfation is the same in the liver
and duodenum. The metabolic modifications of resveratrol can be inhibited
by quercetin, a polyphenol also found in wine (Manach et al., 2004; Santi
et al., 2000a,b).
The clinical and in vivo studies presented here suggest that free trans-
resveratrol in plasma is very sparse and short lived. One reason for the short
half-life may be conjugation of resveratrol. Another reason may be an accumu-
lation of resveratrol in adipose tissue since due to its hydrophobic properties,
albeit this still awaits examination. Resveratrol glucuronides may act as a pool
for active trans-resveratrol. The existence of human β-glucuronidase (Miller
et al., 1990), makes a conversion of resveratrol glucuronide to resveratrol fea-
sible. This implies a steady level of active trans-resveratrol within cells.
1.3 Chemopreventive properties of resveratrol
Carcinogenesis is generally viewed as a multistage process in which molecu-
lar and cellular changes occur. The process spans several years, and can be
simplified to consist of three distinct stages; tumor initiation, promotion, and
progression (reviewed in Jako´bisiak et al., 2003). Resveratrol has been shown
inhibit initiation as well as promotion (reviewed in Surh, 2003).
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In vivo effects of resveratrol on tumorigenesis The first report on
chemopreventive effects of resveratrol was by Jang et al. (1997). The authors
evaluated the effect of resveratrol on tumorigenesis by a two-stage mouse skin
cancer model and found a reduction of skin tumors by as much as 98 %. Since
this first study on the inhibitory effect of resveratrol on tumorigenesis, several
reports have examined the effect of resveratrol on tumorigenesis in different
models.
Resveratrol may have different effects on different types of tumors (ta-
ble 1.2). Resveratrol even at low doses may inhibit development of implanted
hepatoma in different animal models in vivo, and may delay development of
skin cancers when applied topically. Difference in observations may be due to
different times of treatment, but could as easily be explained by differences be-
tween animals or induced versus inherited cancer. Taken together, the results
summarised in table 1.2 indicates an inhibitory effect by resveratrol on the
development of certain tumors in vivo. However, there are some discrepancies
in this field of research and further studies are needed to fully elucidate the
effects of resveratrol.
1.4 Resveratrol modulates the cell cycle
The cell cycle of mammalian cells has several checkpoints to ensure fidelity in
the replication of the DNA and progression through the cell cycle (reviewed
in Bartek and Lukas, 2001). As uncompromised checkpoints ensure that no
cell divides with faulty DNA, nor is able to divide uncontrollably, aberration
in the control of the cell cycle is central to the process of carcinogenesis. A
cell with uncompromised checkpoints could embark on the apoptotic process
of self destruction in the case of irreparable damage. With this reasoning in
mind, the effects of resveratrol on the cell cycle and apoptosis is examined.
1.4.1 Cell cycle progression and check points
The cell cycle is a controlled sequence of events from one division of an eu-
karyotic cell to the next. The cell cycle can be broken down to four phases
(figure 1.2), the first growth phase (G1), the S-phase where the DNA is repli-
cated, a second growth phase (G2), and finally the M-phase, where the cell
actually divides into two daughter cells. Non-dividing cells are said to be in a
resting phase, termed G0.
To control the ordered sequence of events that constitutes the cell cycle,
several control points are essential. The checkpoints ensure that each phase of
the cell cycle is completed before the next is initiated and some checkpoints
ensure that damaged DNA is repaired. The three major checkpoints are at
the G1 to S transition, the G2 to M transition, and the alignment checkpoint
in the M phase (reviewed in Stewart et al., 2003), but also inter S phase
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Figure 1.2: The Cyclins and Cdks of the mammalian cell cycle.
The activity of Cdks fluctuates throughout the cell cycle as a consequence of
fluctuating levels of Cyclins. The cell cycle is initiated by a mitogen. Based
on Coqueret (2003); McGowan (2003); Murray (2004); Price et al. (2004)
checkpoints are known. Given the consequence of erroneous replication of
the DNA, most checkpoints are concentrated between the G1 and G2 phases
(reviewed in Bartek et al., 2001) and these are the focus of this report.
If problems are encountered at a checkpoint the cell may embark on the
process of self destruction, termed apoptosis, as described in section 1.5. In
contrast, malfunctioning cell cycle checkpoints may lead to an accumulation
of mutations and genomic instability, which in turn may lead to development
of cancer.
Cell cycle progression
The passage of a cell through the cell cycle is controlled by a family of kinases
called Cyclin-dependent kinases (Cdks). Binding to specific Cyclins as well as
phosphorylation of the Cdk is necessary for full kinase activity. While the level
of Cdks stays constant throughout the whole cycle, the levels of Cyclins, and
thus the activities of specific Cdks fluctuate with the phase of the cell cycle.
The degradation of Cyclins ensures an unidirectional cell cycle (reviewed in
McGowan, 2003; Miele, 2004; Murray, 2004). Cyclin D is mainly associated
with the G1 phase (figure 1.2), Cyclin E with the G1 to S phase transition,
Cyclin A with the S phase, and Cyclin A and Cyclin B are associated with
the M phase.
Cells in the G1 phase of the cell cycle usually require extracellular signals,
such as growth factors to prepare for entering the S phase. As a response to
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growth factors, Cyclin D is synthesised and activates Cdk4 and Cdk6. The
active kinases phosphorylate the Retinoblastoma protein (RB1), a repressor
of transcription of a number of genes. Inactivation of RB1 results in a sharp
increase in levels of Cyclin E, Cyclin EonCdk2 complex, and transcription of S
phase genes, through activation of the transcription factor E2F. In a positive
feedback loop, Cyclin EonCdk2 phosphorylates RB1 to increase the activity of
the Cyclin EonCdk2 complex (reviewed in Price et al., 2004; Stewart et al.,
2003).
Shortly after the increase in Cyclin E expression, synthesis of Cyclin A is
increased. Where the levels of Cyclin E peaks at the transition from the G1
to S phase, levels of Cyclin A stay high through the whole S phase, to decline
at mid M phase. Towards the end of G2 phase, Cyclin B accumulates in the
cytoplasm. At the beginning of the M phase Cyclin B rapidly translocates
to the nucleus, binds to Cdk1/cdc2 and throws the cell into mitosis. During
the actual division into two daughter cells Cyclin B is degraded, and thus the
divided cells can reenter the G1 phase (reviewed in McGowan, 2003; Price
et al., 2004).
1.4.2 The effect of resveratrol on the cell cycle
When reviewing the literature on the cell cycle modulating effects of resver-
atrol, a complex picture emerges. The majority of authors study the effect
of a single resveratrol concentration at a single treatment time and report
an accumulation in the S phase of the cell cycle. The S phase accumulation
may be correlated to some interference with the DNA polymerases and/or the
ribonucleotide reductase. When varying doses have been analysed, a differ-
ent pattern appears; at low resveratrol concentrations cells accumulate in the
S phase whereas they accumulate and at higher concentrations in the G1 or
G2/M phase.
Resveratrol modulates the cell cycle of many different cell lines In
almost all cell lines studied resveratrol was observed to modulate the progres-
sion through the cell cycle (table 1.3). Observations of cell cycle modulating
effects are not always subjected to statistical analysis. For this reason the
observations presented in table 1.3 should be taken as tendencies which may
not necessarily be statistical significant. Extracting a pattern of cell cycle
modulating effects of resveratrol is not straight forward. However, resveratrol
seems to stimulate an accumulation of cells mainly in the S phase in a dose
dependent manner.
Interference with the DNA polymerases Resveratrol has been
shown to inhibit replication of the SV40 virus (Sun et al., 1998). The SV40
virus makes extensive use of the host replication system why the result
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suggest an interference with the DNA polymerases. Using the calf thymus
DNA polymerases Stivala et al. (2001) found that resveratrol in deed did
inhibit the DNA polymerases α and δ.The authors found no indication of
interference with the assembly of the replication machinery. Taken together,
this suggest that resveratrol interferes with the replication machinery through
a direct inhibition of the DNA polymerase α and δ.
Inhibition of the ribonunleotide reductase An earlier event to trig-
ger S phase delay may be interference with the replication machinery. Resver-
atrol has been shown to inhibit the ribonucleotide reductase (Fontecave et al.,
1998; Pozo-Guisado et al., 2002) which results in depletion of deoxynucleotides
(Horvath et al., 2005). The inhibitory effect on the ribonucleotide reductase
may be due to the anti-oxidant properties of resveratrol, since resveratrol was
found to scavenge the essential tyrosyl radical (Fontecave et al., 1998).
Cell accumulation in different phases depends on the resveratrol
concentration In several cell lines, a complex relationship between resver-
atrol concentration, incubation times, and cell cycle arrest has been reported
(table 1.4).
The general emerging picture is that resveratrol stimulates S phase arrest
at concentrations below a certain level. Above this level, resveratrol stimulates
an accumulation in G1 or G2 phase. A very rough estimate of this level would
be 50 µM. This estimate should be used with precaution, since it is based on
a limited number of observations. Furthermore, the effects of resveratrol on
cell cycle arrest appears to depend on incubation time as well as on cell type.
The cell cycle modulating effect of resveratrol is complex The re-
ports summarised in tables 1.3 and 1.4 indicate a pattern of cell cycle mod-
ulation caused by resveratrol which is complex and internally contradicting.
It appears that resveratrol mainly gives rise to an accumulation of cells in
the S phase. However, this may depend on concentration used, and for colon
carcinomas the effect may also depend on incubation time. Given the limited
number of experiments, these observations may also hold true for other cells
lines.
Table 1.3: Resveratrol stimulates cell cycle arrest in many differ-
ent cell lines. Resveratrol may stimulate S phase accumulation in most
cells. Observations presented here are tendencies, and may not always have
statistical analysis attached
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Phase Model Dose Treatment Reference
range time
None
LNCap 25 µM 96 h Hsieh and Wu (1999)
Seg-1 300 µM 24 h Joe et al. (2002)
SK-Mel-28 100 µM 24 and 48 h Larrosa et al. (2003)
MDA-MB-231a 50 to 150 µM 48 h Pozo-Guisado et al. (2002)
G1
A431 1 to 50 µM 24 h Ahmad et al. (2001)
Bic-1 300 µM 24 h Joe et al. (2002)
HCT-116 100 µM 24 h Fulda and Debatin (2004)
HL-60 100 µM 6, 16, and 24 h Kang et al. (2003)
KATO-III 100 µM 24 h Atten et al. (2001)
LNCap 10 µM 24 and 48 h Narayanan et al. (2003)
Shep 100 µM 24 h Fulda and Debatin (2004)
G1/S
HL-60 10 to 50 µM 48 h Ragione et al. (1998)
K-562 100 µM 24 h Ragione et al. (2003)
S
A549 12.5 to 50 µM 48 h Kim et al. (2003)
Caco2 12.5 to 200 µM 24 h Wolter et al. (2001)
DU145 25 µM 96 h Hsieh and Wu (1999)
Hce7 300 µM 24 h Joe et al. (2002)
HeLa 25 µM 0 to 28 h Zoberi et al. (2002)
HepG2 100 µM 48 h Delmas et al. (2000)
HL-60 300 µM 24 h Joe et al. (2002)
HL-60 4 or 8 µM 20 h Ahmad et al. (2004)
JCA-1 25 µM 96 h Hsieh and Wu (1999)
K-562 100 µM 48 h Ferry-Dumazet et al. (2002)
MCF7 50 µM 6, 12, 24 and 48 h Banerjee et al. (2002)
MCF7 300 µM 24 h Joe et al. (2002)
Ocim2 10 to 50 µM 6 h Estrov et al. (2003)
PC-3 25 µM 96 h Hsieh and Wu (1999)
SK-Mel-28 100 µM 72 and 96 h Larrosa et al. (2003)
SW480 300 µM 24 h Joe et al. (2002)
U-937 10 to 30 µM 24 h Castello and Tessitore (2005)
S/G2
Kcl22 100 µM 48 h Ferry-Dumazet et al. (2002)
G2
HT29 100 µM 32 h Liang et al. (2003)
aSynchronised cells
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Table 1.4: Resveratrol stimulates cell cycle arrest in several cell
lines in a dose dependent manner. Observations presented here are
tendencies, and may not always have statistical analysis attached
Model Phase Dose Treatment Reference
accumulation range time
Human embryonic fibroblasts
S 30 µM 24 h Stivala et al. (2001)
G1/S 90 µM 24 h
MCF7a
S 50 µM 36 h Pozo-Guisado et al. (2002)
G0/G1 100 and 150 µM 36 h
Cem (subline)
S 10, 20 µM 24 h Bernhard et al. (2000)
G1/S 40, 100 µM 24 h
LNCap
S 10 µM 24 h Kuwajerwala et al. (2002)
G1 20, 25 µM 24 h
A2780
S 50 µM 24 h Opipari et al. (2004)
G1 100 µM 24 h
HCT-116
S 50 µM 24 h Wolter et al. (2001)
G2 100 µM 24 h
almost none 200 µM 24 h
SW480
S 30, 50, 100 µM 24 and 48 h Delmas et al. (2002)
S 30 µM 72 h
G2 50, 100 µM 72 h
Caco2
S 25 µM 16/24 h Schneider et al. (2000)
G2 25 µM 40 h
none 25 µM 48 h
S 25 µM 64 h
BPAE
S/G2 50 µM 72 h Hsieh et al. (1999)
S 100 µM 72 h
aSynchronised cells
22
1.5 Resveratrol stimulates apoptosis
1.5.1 Apoptosis
Apoptosis is the term used to describe an evolutionary conserved process which
results in distinct morphological features (Samali et al., 1999). The morpho-
logical changes in vitro include detachment from other cells and the extracel-
lular matrix, resulting in rounding up of the cells. The membrane looses the
asymmetry and starts to bulge out, usually referred to as ‘blebbing’. The nu-
cleus condenses, and eventually disassembles into fragments of multiples of 180
base pairs in length (reviewed in Hengartner, 2000). The entire cell, including
organelles, is organised into vesicles termed ‘apoptotic bodies’ (reviewed in
Ha¨cker, 2000).
Though the term ‘programmed cell death’ was originally coined to refer
specifically to cell death during development (Zhivotovsky, 2004), it is now
frequently used as a synonym to ‘apoptosis’. To avoid the trap of seman-
tics only the word ‘apoptosis’ or the more unspecific ‘cell death’ will be used
throughout this report.
Apoptosis is a complex process involving different proteins and families of
proteins. The purpose of the following sections are to give an overview of the
settings as basis for a discussion of the stimulating effects of resveratrol on
apoptosis.
There are two major pathways involved in apoptosis. The extrinsic path-
way relies on activation of cell surface receptors by external stimuli. The
intrinsic pathway is routed via the mitochondrion as a result of cellular stress
and DNA damage. The cysteine-aspartic-acid-proteases (Caspases) are essen-
tial in both pathways, thus a short description of these proteins will be given.
Activation of the intrinsic pathway converges on a family of proteins called the
Bcl2 family. This family of apoptosis regulating proteins is described before a
more detailed description of the two pathways leading to apoptosis.
Within the cell at least two more apoptosis pathways exist. One where
Caspases are activated by the protease Granzyme B, and one which does not
involve Caspases (reviewed in Reed et al., 2004). These two pathways will not
be discussed further as they are beyond the scope of this report.
The family of Caspases
The key component of the two major pathways in apoptosis is a family of pro-
teases which recognise and cleave right after aspartic acid (reviewed in Gosslau
and Chen, 2004). These aspartic acid specific proteases are collectively called
Caspases and at least 14 mammalian Caspases are known (named Caspase-1
through Caspase-14). Members of the Caspase family are involved in apoptosis
or inflammation, and those involved in apoptosis are generally subdivided into
two groups: the initiator Caspases and effector Caspases (Shi, 2002). Table 1.5
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Table 1.5: Overview of the family of Caspases. Subdivision is based
on Shi (2002)
Apoptosis Inflammation
Initiator Effector
Caspase-2 Caspase-3 Caspase-1
Caspase-8 Caspase-6 Caspase-4
Caspase-9 Caspase-7 Caspase-5
Caspase-10 Caspase-11
Caspase-12
Caspase-13
Caspase-14
summarises the subdivision of the Caspase family. The Caspases involved in
inflammation will not be described further in this report.
Activation of Caspases All Caspases are synthesised as inactive Caspases,
called Procaspases, and must be cleaved for activity. Cleavage of Procaspase
results in a large (20 kDa) and a small (10 kDa) subunit (figure 1.3), and
usually the formation of heterotetramers with two large subunits, two small
subunits, and two active sites (Hengartner, 2000; Lawen, 2003). The large sub-
unit of some active Caspases are cleaved once more, though this is unnecessary
for catalytic activity (Shi, 2002). While the substrate for initiator Caspases
in general are the effector Caspases, the latter are much less selective in their
substrate specificity and activated effector Caspases cleave a wide range of pro-
teins – more than 100 proteins are substrates for activated Caspases (reviewed
in Thiede and Rudel, 2004).
Selected effects of effector Caspases The proteins flipase (moves phos-
pholipids inward with respect to the cytosol), flopase (moves phospholipids
outward) and scramblase (moves phospholipids in both directions) maintain
the assymetry of the plasma membrane, and ensure that Phosphatidylserine
is in the cytosolic side of the plasma membrane (reviewed in Diaz and Schroit,
1996). Activation of Caspase-3 results in exposure of Phosphatidylserine on
the cell surface (figure 1.4), through inhibition of flipase (Hirata et al., 1998;
Mandal et al., 2002).
One hallmark of apoptotic cells is the change in nuclear morphology into
small condensed fragments (Ha¨cker, 2000). Caspase-6 and Caspase-3 cleave
the nuclear mitotic apparatus protein. The cleavage mediates the shrinkage
and fragmentation of nuclei as well as DNA fragmentation and chromatin
condensation (Hirata et al., 1998).
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Active site
Cleavage
CN
(3 - 24 kDa)
Pro-domain Large subunit
(17 - 21 kDa)
Small subunit
(10 - 13 kDa)
Active heterotetramer
Heterodimer
Figure 1.3: Cleavage of Caspases. Procaspase is cleaved to form the
large and small subunit. The active Caspase is a heterotetramer with two
active sites. Based on Hengartner (2000) and Lawen (2003)
(a) Viable or early apoptotic cell (b) Apoptotic cell
(c) Dead cell with faint DNA fragments (d) Dead cell with obvious DNA fragments
Figure 1.4: Double staining of HL-60 cells with Annexin-V-EGFP
and PI. Viable or early apoptotic cell (a), apoptotic cell (b), dead cell with
faint DNA fragments (c), and dead cell with obvious fragments (d). Personal
observations. Cells were treated with 40 µM resveratrol for 18 h, stained with
Annexin-V-EGFP (green) and PI (red), and visualised under a fluorescence
microscope
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Table 1.6: Overview of the human Bcl2 family. Subdivision is based
on the presence of the 1 to 4 Bcl2 homology domains (BH). Based on Borner
(2003)
Anti-apoptotic Pro-apoptotic
Class Name Class Name Class Name
Bcl2-like Bax-like BH3-only
Bcl2 Bax Bik/Nbk
Bcl2L1 v1/Bcl-xL Bak1 Blk
Bcl2L2 Bok/Bcl2L9 Hrk/Dp5
Mcl1 Bcl2L1 v2/Bcl-xS Bnip3
Bcl2A1/Bfl1 Bcl2L11/Bod
Bcl2L10/Bcl-B Bad/Bcl2L8
Bid
PmaiP1/Noxa
Bbc3/Puma
Bmf
The Bcl2 family of pro- and anti-apoptotic proteins
A central family of regulators of apoptosis is the Bcl2 family of pro- and anti-
apoptotic proteins (table 1.6). Some members of the family are anchored in
the mitochondrial membrane by a membrane-anchoring domain, while others
lack the transmembrane domain (Reed et al., 2004). However, the presence of
the transmembrane domain is distributed throughout the whole Bcl2 family
with predominance in the Bcl2-like and Bax-like members (reviewed in Borner,
2003; Hengartner, 2000; Reed et al., 2004).
The extrinsic pathway
The extrinsic pathway is activated by extracellular ligands binding to a
receptor of the tumor necrosis factor receptor superfamily (TNFRSF) and
activation by trimerization of the monomeric receptor (figure 1.5). The
Fas/CD95 receptor is the most well-describeed of the extrinsic pathway,
but also TNFRSF1A/TNF-R1 is often cited in the literature. The ligand
FasLG/CD95L activates the Fas/CD95 receptor which in turn activates
Caspase-8. Activated Caspase-8 stimulates cleavage and activation of differ-
ent effector Caspases as well as the pro-apoptotic protein Bid. by cleavage to
tBid. In turn tBid activates the intrinsic pathway (reviewed in Gosslau and
Chen, 2004; Lawen, 2003; Muppidi et al., 2004).
26
Caspase-6
Caspase-7
Bax/Bcl2↑
Caspase-8 tBid
Cytochrome c
Cytochrome conApaf-1onProcaspase-9
(Apoptosome)
Caspase-3
Fas
FasLG
Figure 1.5: The pathways of apoptosis. Simplified illustration to
show the Caspase activation pathways. In the extrinsic pathway (gray area),
extracellular ligands, such as the Fas/CD95 ligand FasLG/CD95L, bind to
membrane bound receptors and result in activation of the initiator Caspase-
8. In the intrinsic pathway, intracellular stress signals lead to activation
of the intrinsic pathway, resulting in increase in the Bax/Bcl2 ratio, subse-
quent Cytochrome c release from mitochondria and activation of the effector
Caspase-3. Caspase-8 may cleave Bid to tBid, which in turn may activate
the intrinsic pathway (reviewed in Gosslau and Chen, 2004; Guseva et al.,
2004; Lawen, 2003; Muppidi et al., 2004; Shiozaki and Shi, 2004)
The intrinsic pathway
In the intrinsic pathway, apoptosis is activated when Cytochrome c is re-
leased from the intramembrane space of the mitochondrion into the cytosol
(figure 1.5). This release is under tight control by the Bcl2 protein family.
The Bax/Bcl2 ratio indicates the relative amounts of pro- and anti-apoptotic
proteins of the Bcl2 family (reviewed in Gosslau and Chen, 2004).
The Bax/Bcl2 ratio goes up as response to stimuli such as DNA damage
(through p53) and reactive oxygen species. Members of the Bcl2 family stim-
ulates release of Cytochrome c and other proteins from the intramembrane
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space into the cytosol. Cytosolic Cytochrome c binds to apoptotic protease
activating factor 1 which stimulates binding of Procaspase-9 to form the ma-
ture complex known as the apoptosome. When bound to the apoptosome,
Procaspase-9 is activated. Activated Caspase-9 on the apoptosome activates
the effector Caspases 3, 6, and 7 by cleavage of their respective Procaspases
(reviewed in Lawen, 2003; Shi, 2002).
1.5.2 The effect of resveratrol on apoptosis
There is accumulating evidence that resveratrol stimulates apoptosis in many
different tumor cell lines (table 1.7). Few cancer cells are unaffected by resver-
atrol, and the lack of effect can partly be explained by usage of a sub-effective
dose and difference in incubation time.
Caspase dependent stimulation of apoptosis
In reports where the effect on Caspase-3 is studied is the activity of Caspase-3
stimulated by resveratrol. This clearly indicates that resveratrol stimulates a
Caspase dependent cell death. Utilising different inhibitors of the active site
of Caspases it is possible to study the role of a given Caspase in apoptosis. A
selection of Caspase inhibitors are listed in table 1.8
Using z-VAD-fmk, a general Caspase irreversible inhibitor, and z-DEVD-
fmk, a specific Caspase-3 irreversible inhibitor, only a reduction in cell death
is found in several cell lines (Clement et al., 1998; Estrov et al., 2003; Opipari
et al., 2004; Roman et al., 2002). The z-DEVD-fmk and the specific Caspase-
8 inhibitor z-IETD-fmk had limited reducing effect on apoptosis stimulated
by resveratrol in SW480 cells (Delmas et al., 2003). Only when cells were
treated with z-VAD-fmk was apoptosis nearly abolished. In HCT-116, another
colon cancer cell line, z-DEVD-cho, a specific Caspase-3 reversible inhibitor,
only reduces apoptosis, and z-IETD-cho had no significant effect on apoptosis
stimulated by resveratrol (Mahyar-Roemer et al., 2001). Altogether, the re-
sults indicate that resveratrol may stimulate Caspase dependent apoptosis, in
certain cell lines.
The extrinsic pathway may be involved in resveratrol stimulated
apoptosis Resveratrol has been shown to stimulate expression of the
Fas/CD95 ligand, FasLG/CD95L, in HL-60 (Clement et al., 1998; Pervaiz,
2001; Su et al., 2005), SNU-1, and KATO-III (Atten et al., 2005) cells.
This indicates that the extrinsic pathway may be involved in resveratrol
Table 1.7: Resveratrol stimulates apoptosis in many different cell
lines. The difference in stimulatory effect in Caco2 and K-562 cells in differ-
ent experiments may be due to used resveratrol concentration and/or incu-
bation times
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Model Dose Treatment Reference
range time
No effect
Caco2 50 µM 48 h Schneider et al. (2000)
JCA-1 25 µM 96 h Hsieh and Wu (1999)
MDA-MB-231 0 to 200 µM 48 h Pozo-Guisado et al. (2002)
Minor effect
HL-60 10 to 50 µM 48 h Ragione et al. (1998)
K-562 100 µM 24 h Ragione et al. (2003)
Stimulating effect
Caco2 200 µM 24 and 48 h Wolter et al. (2001)
K-562 30 and 100 µM 72 h Ferry-Dumazet et al. (2002)
K-562 100 µM 24 h Roy et al. (2002)
Eskol and Wsu-Cll 3 to 50 µM 0 to 48 h Roman et al. (2002)
A2780 50 and 100 µM 24 h Opipari et al. (2004)
A431 1 to 25 µM 24 h Ahmad et al. (2001)
A549 12.5 to 50 µM unknown Kim et al. (2003)
Cem (subline) 0 to 100 µM 24, 48, and 72 h Bernhard et al. (2000)
DU145 25 µM 96 h Hsieh and Wu (1999)
HCT-116 0 to 100 µM 48 and 72 h Delmas et al. (2003)
HeLa 100 µM 24 h Roy et al. (2002)
HL-60 32 µM 24 h Clement et al. (1998)
HL-60 25 µM 24 h Kang et al. (2003)
HL-60 32 µM unknown Pervaiz (2001)
HL-60 100 µM 24 h Roy et al. (2002)
HL-60 20 µM 24 h Su et al. (2005)
HL-60 100 µM 6, 24, and 48 h Surh et al. (1999)
Jurkat 30 µM 72 h Ferry-Dumazet et al. (2002)
KATO-III 100 µM 24 and 48 h Atten et al. (2001)
Kcl22 30 µM 72 h Ferry-Dumazet et al. (2002)
LNCap 25 µM 96 h Hsieh and Wu (1999)
LNCap 10 µM 24 and 48 h Narayanan et al. (2003)
MCF7 0 to 150 µM 36 h Pozo-Guisado et al. (2005)
MCF7 100 µM 24 h Roy et al. (2002)
MCF7 0 to 200 µM 36 h Pozo-Guisado et al. (2002)
MiaPaca-2 25 to 100 µM 72 and 24 h Mouria et al. (2002)
PC-3 25 µM 96 h Hsieh and Wu (1999)
SNU-1 1 to 100 µM 24 and 48 h Atten et al. (2005)
SW480 0 to 100 µM 48 and 72 h Delmas et al. (2003)
Thp-1 100 µM 72 h Ferry-Dumazet et al. (2002)
U-937 30 µM 72 h Ferry-Dumazet et al. (2002)
Ocim2 5 to 100 µM 18 h Estrov et al. (2003)
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Table 1.8: Selected Caspase inhibitors.
Inhibitor Target Irreversible
z-DEVD-cho Caspase-3 No
z-DEVD-fmk Caspase-3 Yes
z-IETD-cho Caspase-8 No
z-IETD-fmk Caspase-8 Yes
FAM-LETD-fmk Caspase-8 Yes
z-VAD-cho General No
z-VAD-fmk General Yes
stimulated apoptosis. Concomitant treatment of HL-60 and T47D cells
with anti-Fas/CD95 and resveratrol inhibited resveratrol induced cell death
(Clement et al., 1998). Since anti-Fas/CD95 in an inhibitor of activation of
the receptor, this observation is another indication that resveratrol stimulated
apoptosis indeed does involve the extrinsic pathway.
Activation of the Fas/CD95 system, and thus the extrinsic pathway may
be cell type specific, since no increase in levels of Fas/CD95 or FasLG/CD95L
was observed in resveratrol treated Cem (Bernhard et al., 2000) and SW480
cells (Delmas et al., 2003). Interestingly, the authors found that although
no interaction is needed between Fas/CD95 and it’s ligand, interference with
proteins of the death inducing signaling complex inhibits resveratrol stimulated
apoptosis. This indicates that resveratrol may stimulate apoptosis through the
Fas/CD95 activated extrinsic pathway, independently of FasLG/CD95L but
through redistribution of Fas/CD95 in the membrane.
The intrinsic pathway may be activated by resveratrol, but the pre-
cise mechanism is unclear An increase in cytosolic Cytochrome c follow-
ing treatment with resveratrol has been reported in several cell lines (Delmas
et al., 2003; Opipari et al., 2004; Pervaiz, 2001) indicating that resveratrol
activates the intrinsic pathway as well.
Changes in the Bax/Bcl2 ratio are associated with activation of the in-
trinsic pathway (reviewed in Gosslau and Chen, 2004). The role of the Bcl2
family in resveratrol stimulated apoptosis remains obscure. A decrease in the
anti-apoptotic proteins Bcl2, Mcl1, and Bcl2L1 v1/Bcl-xL, and an increase in
the pro-apoptotic proteins Bax and Bak1 following resveratrol treatment has
been reported in different cell lines (Delmas et al., 2003; Estrov et al., 2003;
Pozo-Guisado et al., 2005; Roman et al., 2002; Surh et al., 1999). However,
overexpression of Bcl2 and Bcl2L1 v1/Bcl-xL failed to inhibit Cytochrome c
release and apoptosome formation in the ovarian A2780 cells (Opipari et al.,
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2004). In contrast, overexpression of Bcl2, in the human breast cancer cell
line MCF7, nearly abolished apoptosis (Pozo-Guisado et al., 2005). This indi-
cates, that at least in some cells, resveratrol may activate the intrinsic pathway
independently of the Bcl2 family of anti- and pro-apoptotic proteins.
Caspase independent stimulation of cell death
Resveratrol inhibits the rat liver mitochondrial F0F1-ATPase activity (Zheng
and Ramirez, 1999) and rat brain F0F1-ATPase (Zheng and Ramirez, 2000),
but has no effect on Na+/K+-ATPase from porcine cerebral cortex (Zheng and
Ramirez, 2000). Resveratrol inhibits extracellular ATP synthesis in human
umbilical vein endothelial cells. No effect was observed on intracellular ATP
synthesis (Arakaki et al., 2003, observation presented without data). ATPase
inhibitors may stimulate apoptosis in some cell lines (Wolvetang et al., 1994)
but suppress and delay apoptosis in others (Shchepina et al., 2002).
1.6 Resveratrol and NF-κB
1.6.1 The NF-κB family of transcription factors
Nuclear factor κB (NF-κB) proteins are transcription factors, which have been
shown to be involved in regulation of at least 200 genes (Loop and Pahl, 2003;
Pahl, 1999). In addition, more than 100 genes have been predicted to contain
recognition sites for the transcription factors by computer-based methods (She-
lest et al., 2003). The genes targeted by NF-κBs are involved in a large array
of cellular events, such as immune and inflammatory responses, cell prolifera-
tion and apoptosis. Dysfunctional NF-κBs has been shown to be involved in a
number of diseases, including heart diseases and cancer (Aggarwal, 2004; Dorai
and Aggarwal, 2004; Libby, 2002; Robbesyn et al., 2004). A small selection of
NF-κB target genes are listed in table 1.9. For an updated and comprehensive
(albeit unrefereed) list, consult the website http://www.nf-kb.org.
The components of NF-κB controlled gene expression The five mem-
bers of the mammalian family of NF-κBs are shown in table 1.10. The mem-
bers are defined by their Rel homology domain (RHD), which is reponsible for
DNA binding (reviewed in Chen and Greene, 2004). All members form homo-
and heterodimers with each other, all with the capability of stimulating gene
transcription. The only exception is RelB which only forms heterodimers with
NF-κB1 p105/p50 or NF-κB2 p100/p52 and which acts as a transcriptional
activator as well as a repressor (reviewed in Chen and Greene, 2004; Verma,
2004). Furthermore, homodimers of NF-κB1 p105/p50 and NF-κB2 p100/p52
may act as transcription repressors by binding to NF-κB sites on the DNA
(Verma, 2004).
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Table 1.9: A small selection of genes shown to be controlled by
NF-κBs. Based on Loop and Pahl (2003)
Gene Function
Regulators of apoptosis
Bax Pro-apoptotic
Bcl2 Anti-apoptotic
Bcl2L1 v1/Bcl-xL Anti-apoptotic
Bcl2A1/Bfl1 Anti-apoptotic
Bcl2L10/Bcl-B Anti-apoptotic
Fas/CD95 Pro-apoptotic
FasLG/CD95L Pro-apoptotic
CFLAR/FLIP Anti-apoptotic
Cell cycle
Cyclin D1 Cell-cycle regulation
Cyclin D2 Cell-cycle regulation
Cyclin D3a Cell-cycle regulation
E2F3 Cell cycle regulator
CdkN1A/p21/Cip1/Waf1a Cyclin-dependent kinase inhibitor
Transcription factors
Myc/c-Myc Transcription factor
Rel/c-Rel Transcription factor
RelB Transcription factor
NF-κBiA/IκBα Inhibitor of NF-κB
NF-κBiZ/IκBζ/Mail Inhibitor of NF-κB
NF-κB1-105kDa NF-κB1-50kDa precursor
NF-κB2-100kDa NF-κB2-52kDa precursor
p53 Tumor suppressor
Cytokines
TNF-α Tumor necrosis factor
IL-1β Interleukin 1, beta
Stress response
Nos2A/iNos Inducible nitric oxide synthase
aIndicates presence of a NF-κB site in the promoter, but not shown to be controlled by NF-κBs
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Table 1.10: Overview of the NF-κB family, its inhibitors and the
inhibitor kinases. Based on Bonizzi and Karin (2004); Chen and Greene
(2004); Hayden and Ghosh (2004); Wong and Chung (2003)
Proteins Complexes with
NF-κB
Rel/c-Rel Rel/c-Rel, RelA/p65,
NF-κB1 p105/p50, NF-κB2 p100/p52
RelA/p65 RelA/p65, Rel/c-Rel,
NF-κB1 p105/p50, NF-κB2 p100/p52
RelB no homodimer,
NF-κB1 p105/p50, NF-κB2 p100/p52
NF-κB1 p105/p50 NF-κB1 p105/p50, Bcl3/Bcl4,
Rel/c-Rel, RelA/p65, RelB
NF-κB2 p100/p52 NF-κB2 p100/p52, Bcl3/Bcl4,
Rel/c-Rel, RelA/p65, RelB
NF-κB inhibitors (NF-κBi/IκB)
NF-κBiA/IκBα All NF-κB dimers
NF-κBiB/IκBβ All NF-κB dimers
NF-κBiE/IκB All NF-κB dimers
NF-κBiZ/IκBζ/Mail All NF-κB dimers
Bcl3/Bcl4 All NF-κB dimers
NF-κB inhibitor kinases (IKBK/IKK)
Chuk/IKK-α Unknown
IKBKB/IKK-β Unknown
IKBKG/IKK-γ/Nemo Unknown
IKBKE/IKK- Unknown
NF-κB translocates to the nucleus where it exerts the transcriptional ac-
tivity. By masking the nuclear localisation sequence of the RHD (Karin et al.,
2004), NF-κBs are mainly kept inactive in the cytosol. This activity control
is carried out by a family of at least five proteins, collectively called NF-κB
inhibitor (NF-κBi/IκB) (table 1.10) (reviewed in Wong and Chung, 2003).
The family is defined by their ankyrin repeats which makes unprocessed NF-
κB1 p105/p50 and NF-κB2 p100/p52 a member of this family as well (Karin
et al., 2004).
In order to release and thus activate NF-κBs, the NF-κBi/IκB must
be phosphorylated by a NF-κB inhibitor kinase (IKBK/IKK) (reviewed in
Hayden and Ghosh, 2004). The known IKBK/IKKs are listed in table 1.10.
The most common form of the IKBK/IKK complex consists of the cat-
alytic subunits Chuk/IKK-α and IKBKB/IKK-β and the regulatory subunit
IKBKG/IKK-γ/Nemo (Bonizzi and Karin, 2004).
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Figure 1.6: The NF-κB activation pathways. Simplified illustra-
tion to show the NF-κB activation pathways. In the classical pathway
(left), NF-κBiA/IκBα is marked for degradation by phosphorylation (℗)
by IKBKB/IKK-β. The uninhibited complex is phosphorylated before entry
into the nucleus. In the alternative pathway (right), NF-κB2 p100/p52 is
marked for proteolytic processing by phosphorylation be Chuk/IKK-α. The
processed complex then translocated to the nucleus. Based on Bonizzi and
Karin (2004); Chen and Greene (2004); Karin et al. (2004)
The NF-κB activation pathways There are in general two pathways lead-
ing to NF-κB mediated enhanced transcription of a gene: the classical pathway
and the alternative pathway, recently reviewed in Bonizzi and Karin (2004).
Both NF-κB activation pathways are activated by pro-inflammatory cytokines
such as tumor necrosis factor (TNF-α) and interleukin 1, beta (IL-1β) (Bonizzi
and Karin, 2004; Chen and Greene, 2004). In addition to cytokines, the classi-
cal pathway is also activated by stimuli such as stress, bacteria via the Toll-like
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receptor, and viral infection (reviewed in Bonizzi and Karin, 2004). Depend-
ing on the pathway activated, different genes are expressed (Chen and Greene,
2004)
The classical NF-κB activation pathway RelA/p65onNF-κB1-50kDa
and RelA/p65onNF-κB2-52kDa complexes are kept in the cytosol by attach-
ment to NF-κBiA/IκBα, see figure 1.6. The IKBK/IKK complex acts predom-
inantly through IKBKB/IKK-β in a IKBKG/IKK-γ/Nemo controlled fash-
ion. Activated IKBK/IKK catalyses phosphorylation of NF-κBiA/IκBα of the
RelA/p65onNF-κB1-50kDaonNF-κBiA/IκBα complex at serine residues near
the N-terminal. The phosphorylation targets NF-κBiA/IκBα for ubiquitina-
tion and subsequent degradation by the 26S proteasome. The uninhibited
RelA/p65onNF-κB1-50kDa complex is phosphorylated (Sakurai et al., 1999,
2003) and rapidly translocates to the nucleus where is helps general transcrip-
tion factors and the RNA polymerase to assemble on the DNA (reviewed in
Hayden and Ghosh, 2004). A negative feedback mechanism is provided by the
NF-κB stimulated expression of NF-κBiA/IκBα, but increased expression of
cytokines such as TNF-α and IL-1β, may also be the result of activation of
the classical NF-κB pathway (Bonizzi and Karin, 2004; Verma, 2004)
The alternative NF-κB activation pathway This pathway is some-
times refered to as the canonical pathway. In contrast to the classical NF-κB
activation pathway, the alternative pathway depends strictly on Chuk/IKK-
α (figure 1.6) (reviewed in Karin et al., 2004). The inactive RelBonNF-κB2
p100/p52nfkb2:100 complex is activated by a Chuk/IKK-α homodimer, by
phosphorylation of NF-κB2-100kDa at two C-terminal sites. This phosphory-
lation is necessary for ubiquitination of NF-κB2-100kDa and subsequent prote-
olytic processing of NF-κB2-100kDa to NF-κB2-52kDa. The active RelBonNF-
κB2-52kDa complex translocates into the nucleus, and causes increased gene
transcription (reviewed in Bonizzi and Karin, 2004).
1.6.2 The effect of resveratrol on NF-κB
The effect of resveratrol on unstimulated cells The effect of resveratrol
on NF-κB activation in unstimulated cells is not consistent (table 1.11). Some
results point to a positive effect of resveratrol on the NF-κB activity, while
other observations show a negative effect or no effect at all. Some of the
variability may be due to the concentrations used and/or incubation times,
which could be sub-effective. Another reason for the diverging observations
could be due to cell type specific effects of resveratrol.
The effect of resveratrol on stimulated cells In contrast to the vari-
able effects reported of resveratrol on unstimulated cells, the effect on cytokin
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stimulated cells is far more consistent (table 1.12). Resveratrol generally in-
hibits the activity of NF-κB, and the effect appears to be independent of fac-
tors such as pretreatment duration and chemical properties of the stimulatory
compound.
The only stimulatory effect on NF-κB by resveratrol has been reported
using the colon carcinoma cell line HT29. Resveratrol used in doses of 25,
50 and 100 µM caused an increase in the levels of the luciferase gene product
in a dose dependent fashion (Jeong et al., 2004). The NF-κB stimulatory
effects of resveratrol appeared to peak at 50 µM, as 100 µM yielded less gene
product. However, no statistical analysis was performed, so the significance of
the observation is left to be determined.
1.7 Purpose
Resveratrol has been shown to exert a variety of cellular effects. 1) The cell
cycle is modulated in a complex manner, where the phase affected depends on
the resveratrol concentration used, incubation time, and cell type. 2) Apop-
tosis is stimulated mainly through the intrinsic pathway, though the extrinsic
pathway is also activated. 3) Activation of NF-κB is inhibited.
The purpose of this study was to identify the effect of resveratrol on DNA
synthesis and cell cycle progression. The apoptosis stimulating properties of
resveratrol were also studied, as well as the possible role of NF-κB in cell cycle
modulation and apoptosis.
Model of choice A suspension human promyelocytic leukemia cell line (HL-
60), and an epithelial human hepatoma-derived cell line (HepG2), were chosen
as models. Resveratrol has previously been shown to modulate the cell cycle
of HL-60 and HepG2 cells (Ahmad et al., 2004; Delmas et al., 2000; Joe et al.,
2002). The apoptosis stimulating effects of resveratrol on HL-60 cells is well
established, though activation of the extrinsic pathway is not yet fully eluci-
dated (Clement et al., 1998; Kang et al., 2003; Pervaiz, 2001; Roy et al., 2002;
Surh et al., 1999; Su et al., 2005). Furthermore, resveratrol has been shown to
be cytotoxic to different leukemia cells without any severe effect on normal pe-
riphal blood cells (Do¨rrie et al., 2001; Gautam et al., 2000; Tsan et al., 2002).
The effect of resveratrol on NF-κB activation in HL-60 cells has not yet been
reported.
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Chapter 2
Materials and methods
2.1 Chemicals and reagents
Resveratrol, Camptothecin, TNF-α, Neutral Red (NR), 4’,6-Diamidino-2-
phenylindole (DAPI), Actinomycin-D, tetrazolium salt (MTT), bovine serum
albumin (BSA), DMSO, nonfat dried milk, and anti-α-Tubulin were all
obtained from Sigma. RPMI-1640, L-Glutamine, fetal calf serum (FCS), Glu-
tamax, Hygromycin, LDS 4× Sample Buffer, NuPAGE 10× Sample Reducing
Agent, MES-SDS buffer, antioxidant, and Transfer buffer were from Invit-
rogen. Phosphate buffered saline (PBS), Penicillin-Streptomycin-Glutamine
mix (10000 units/ml penicillin, 10000 µg/ml streptomycin and 29.2 mg/ml
L-Glutamine), and trypsin-EDTA were purchased from Gibco. Dulbecco’s
modified Eagle’s medium (DMEM) was obtained from Cambrex. NaCl,
NaH2PO4, ethanol, and methanol were from Merck. Chaps Cell Extract
Buffer, DTT, Antibodies against Caspase-3, cleaved Caspase-3, RelA/p65,
phosphorylated RelA/p65 (Ser536), and peroxidase-labelled anti-rabbit IgG
were purchased from Cell Signaling. β-Actin and GAPDH antibodies were
obtained from Abcam. 4 % Paraformaldehyde in phosphate buffer, pH 7.4
was from Bie & Berntsen. Phosphatase Inhibitor Set II and Protease Inhibitor
Set III were purchased from Calbiochem. Tween-20 was obtained from ICN,
and Restore Western Blot Stripping Buffer was from Pierce.
Resveratrol and Actinomycin-D were diluted in DMSO and kept at -20 ◦C
until used. TNF-α was kept in aliquots at -20 ◦C and diluted in cultivation
medium prior to use. No compound was stored for more than 6 months.
2.2 Cell lines
HL-60, a suspension human promyelocytic leukemia cell line, and HepG2, an
epithelial human hepatoma-derived cell line, were obtained from the American
Tissue Culture Collection. The epithelial human cervical carcinoma derived
cell line, HeLa stably transfected with a luciferase reporter gene under the
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transcriptional control of the NF-κB promoter (HeLa-pNF-kB-Luc) was the
gracious gift of Claus Bekker Jeppesen, Novo Nordisk A/S.
Cell media The HL-60 cells were cultivated in RPMI-1640 supplemented
with 200 mM L-Glutamine and 10 % heat-inactivated FCS.
The HepG2 cells were cultivated in DMEM supplemented with 1 %
Penicillin-Streptomycin-Glutamine mix and 10 % heat-inactivated FCS.
The HeLa-pNF-kB-Luc cells were cultivated in DMEM supplemented with
1 % Penicillin-Streptomycin-Glutamine mix, 400 µg/ml Hygromycin, and 10 %
heat-inactivated FCS. For the luciferase gene expression assays, the HeLa-
pNF-kB-Luc cells were assayed in DMEM without phenol red supplemented
with 10 mM Hepes, 2 mM Glutamax, and 10 % heat-inactivated FCS.
Cell cultivation All cells were maintained in a humidified 37 ◦C, 5 % CO2
incubator. When the cell density reached approximately 80 % confluence, cells
were subcultivated. HL-60 cells were subcultivated by diluting cells in fresh
cultivation medium to approximatly 2× 105 cells/ml. HepG2 and HeLa-pNF-
kB-Luc were detached by trypsin-EDTA, and reseeded at approximatly 4×104
and 2× 104 cells/cm2, respectively. No cell line was passaged more than 30
times. All cell culture flasks as well as 96-well microtiter plate and 6-well
Multidishes were fron Nunc, unless otherwise specified.
2.3 Thymidine incorporation assay
This assay utilises the incorporation of 3H-labelled thymidine into newly syn-
thesised DNA. Radioactivity is used as an index of cells progressing through
the S phase of the cell, and thus an index of cell growth.
2.3.1 Cell treatment – HL-60
Variation 1 – concurrent resveratrol addition Exponentially grow-
ing HL-60 cells were diluted in fresh cultivation medium to 3× 104 cells/ml.
The cell suspension was passed in aliquots to centrifugal tubes (VWR Inter-
national) and resveratrol or vehicle was added to obtain appropriate concentra-
tion (0.1 % vehicle). The cell suspensions were transferred to a sterile 96-well
microtiter plate to a total volume of 200 µl/well. All outer wells received 200 µl
PBS. Cells were left in the incubator for the desired duration. Thymidine was
added and cells were harvested as described in ‘Cell harvest and scintillation
count’.
Variation 2 – asynchronous resveratrol addition Exponentially grow-
ing HL-60 cells were diluted in fresh cultivation medium to 6× 104 cells/ml.
The cell suspension was passed to a sterile 96-well microtiter plate to a total
40
volume of 100 µl/well. Stock solutions of resveratrol or vehicle (0.1 %) in cul-
tivation medium was made and was kept in the dark in a standard incubator.
At different time points prior to cell harvest, 100 µl resveratrol stock solution
was passed to each well of the 96-well microtiter plate to a final volume of
200 µl/well. All outer wells received 200 µl PBS. The plates were left in the
incubator for the desired incubation time. Thymidine was added and cells
were harvested as described in ‘Cell harvest and scintillation count’.
2.3.2 Cell treatment – HepG2
Exponentially growing HepG2 cells were diluted in fresh cultivation medium to
3× 104 cells/ml and transferred to a sterile 96-well microtiter plate to a total
volume of 200 µl/well. All outer wells received 200 µl PBS. Cells were placed
in the incubator and allowed to adhere overnight. At the day of experiment,
stock solutions of resveratrol or vehicle (0.1 %) in cultivation medium were
made in centrifugal tubes (VWR International) and kept in the dark in the
incubator. At different time points prior to cell harvest, medium was removed
by gently inverting the plates, 200 µl resveratrol stock solution was added to
each well. All outer wells received 200 µl PBS. The plates were left in the
incubator for the desired incubation time. Thymidine was added and cells
were harvested as described in ‘Cell harvest and scintillation count’.
2.3.3 Cell harvest and scintillation count
Two hours before harvest 20 µl 6.25 µCi/ml 3H-Thymidine (Amersham Bio-
sciences) was added to each well, and the plates were left in the incubator.
After incubation, cells were transferred to filter plates (PerkinElmer) by the
use of a cell harvester (Packard) and left to dry overnight. 30 µl Microscint
O scintillation liquid (PerkinElmer) was added to each well of the dried fil-
ter plates, and the plates were read in a TopCount NXT scintillation counter
(Packard). The TopCount NXT was controlled by the TopCount NXT version
1.06 (Packard) external software on Windows 95.
2.4 Light-absorption scan
The difference in absorption maxima for cis- and trans-resveratrol was used to
qualitatively determine whether trans-resveratrol disappears from a solution.
PBS with or without 10 % heat inactivated FCS was left with vehicle, 40 or
80 µM resveratrol in centrifugal tubes (VWR International) in a humidified
37 ◦C, 5 % CO2 incubator. After 0 to 7 days the solutions were transferred to
a UV-transparent 96-well microtiter plate (Costar) to a total volume of 100 µl.
The absorption spectra in the range of 200 to 1000 nm were obtained using a
SpectraMax Plus 384 (Molecular Devices) microplate spectrophotometer con-
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trolled by the SoftMax Pro version 4.7.1 (Molecular Devices) external software
on Windows 2000.
2.5 Cell viability estimations
2.5.1 MTT assay
In MTT and other tetrazolium salt based assays insoluble formazan crystals
are generated by enzymatic cleavage. The needed enzyme belongs to the
respiratory chain of the mitochondria, although one report suggests the cytosol
as being the primary residence (Bernas and Dobrucki, 2002). The assay was
performed as described by Holian and Walter (2001).
Exponentially growing HepG2 cells were diluted in fresh cultivation
medium to 3× 104 cells/ml and transferred to a sterile 96-well microtiter
plate to a total volume of 200 µl/well. All outer wells received 200 µl PBS.
Cells were placed in the incubator and allowed to adhere overnight. At the
day of treatment, cultivation medium was changed to cultivation medium
with resveratrol, TNF-α with Actinomycin-D, TNF-α with vehicle (0.1 %),
or vehicle (0.1 %). All outer wells received 200 µl PBS. The plates were left
in the incubator for the desired incubation time.
Two hours prior to the end of incubation, 25 µl MTT (5 mg/ml diluted in
dH2O) was added to each well. After incubation, the MTT-medium mixture
was discarded by gently inverting the plate. 200 µl DMSO was added to each
well, and the plates were left on an orbital shaker for 5 min until all formazan
crystals had dissolved. The optical density was read at 550 nm with 650 nm as
reference wavelength on a SPECTRA Rainbow Absorbance Microplate Reader
(Tecan). The SPECTRA Rainbow was controlled by the Magellan version 2.0
(Tecan) external software on Windows 95.
2.5.2 NR assay
This assay is based on the simple principle of active dye uptake by viable
cells. HL-60 cells were stained with Neutral Red (NR) as previously described
(Lowik et al., 1993; Rooseboom et al., 2002). Briefly; HL-60 cells were diluted
to 3× 104 cells/ml in cultivation medium. The cell suspension was passed in
aliquots to centrifugal tubes (VWR International) and resveratrol or vehicle
was added to obtain appropriate concentration (0.1 % vehicle). The cell sus-
pensions were transferred to a sterile 96-well microtiter plate to a total volume
of 200 µl/well. All outer wells received 200 µl PBS. Cells were incubated in
the incubator for the desired incubation time.
Stock solution of 1 mg/ml NR was made by dissolving the dye in dH2O,
sterilised by filtering through a serum filter with a pore size of 0.2 µm (Nal-
gene), and shielded from light. A dye buffer was made from one part 1 mg/ml
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NR stock solution and one part sterile 1.8 % NaCl. Two hours before destain-
ing, 50 µl dye buffer was added to each well and the plates were left in the
incubator. After incubation, cells were pelleted by centrifugation (400 g at
20 ◦C for 10 min), and medium was discharged by inverting the plate. 100 µl
destaining buffer (0.05 M NaH2PO4 in 50 % (v/v) ethanol) was added to each
well, and the plates were left on an orbital shaker for 15 min. The optical den-
sity was read at 550 nm with 650 nm as reference wavelength on a SPECTRA
Rainbow Absorbance Microplate Reader (Tecan). The SPECTRA Rainbow
was controlled by the Magellan version 2.0 (Tecan) external software on Win-
dows 95.
2.6 Analysis by flow cytometry
2.6.1 Cell cycle analysis by PI staining
The distribution of cells in the cell cycle was analysed by the CycleTEST Plus
DNA Reagent Kit (BD Biosciences). The assay is based on the method by
Vindeløv et al. (1983) where nuclei are isolated using a mixture of a non-
ionic detergent and trypsin. The DNA is subsequently stained with the DNA
binding dye Propidium Iodine (PI).
The assay was performed according to manufacturer’s protocol. Exponen-
tially growing HepG2 cells were seeded at 1× 105 cells/ml in 10 ml one day
prior to resveratrol treatment and left to settle in a T25 flask. At the day
of treatment, cultivation medium was changed to cultivation medium with
resveratrol or vehicle (0.1 %). HL-60 cells were diluted to 3.5× 105 cells/ml in
fresh cultivation medium, resveratrol or vehicle (0.1 %) was added, and 3 ml
cell suspensions were passed to each well of a sterile 6-well Multidish.
After tratment for 24 h 1× 106 cells were pelleted by centrifugation (400 g
at 4 ◦C for 5 min), washed twice with PBS, and incubated at room tempera-
ture with a buffer containing trypsin and a non ionic detergent. After 10 min
trypsin inhibitor in RNase buffer was added, and cells were incubated at room
temperature for 10 min. Subsequently, PI was added, and cells were incubated
on ice for 10 min. Stained cells were analysed as described in ‘Flow cytometric
parameters’ using the fluorescence intensity height, channel 2 (FL2-H) param-
eter. The size of nuclei was obtained using the forward scatter height (FSC-H)
(particle size) parameter.
The approximate excitation and emission peaks of DNA bound PI are
535 nm and 617 nm, respectively.
2.6.2 Determination of cell size and granularity
To determine the effect on cell size and granularity, intact cells were analysed
by the use of the FSC-H (particle size) and side scatter height (SSC-H) (parti-
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cle complexity, (i.e. the amount and type of cytoplasmic granules) parameters
of the flow cytometer.
HepG2 cells were seeded at 1× 105 cells/ml in 10 ml one day prior to
resveratrol treatment and left to settle in a T25 flask. At the day of treatment,
cultivation medium was changed to cultivation medium with resveratrol or ve-
hicle (0.1 %). HL-60 cells were diluted to 3.5× 105 cells/ml in fresh cultivation
medium and resveratrol or vehicle (0.1 %) was added, and 3 ml cell suspen-
sions were passed to each well of a sterile 6-well Multidish. Before analysis by
flow cytometry, HepG2 cells were detached from the flask by trypsin-EDTA
and resuspended in fresh cultivation medium. HL-60 cells were briefly resus-
pended to ensure a uniform cell distribution. Cells in suspension were analysed
as described in ‘Flow cytometric parameters’.
2.6.3 Apoptosis evaluation by Annexin-V binding analysis
Apoptosis was evaluated by the Annexin V-EGFP Apoptosis Detection Kit
(Stratech Scientific). The assay is based on the observations that apoptotic
cells have lost the membrane asymmetry and exposes Phosphatidylserine (PS).
Annexin-V binds to PS, and when conjugated to a fluorophor (enhanced green
fluorescent protein (EGFP) in this case), the increase in bound Annexin-V, and
thus an increase in apoptosis, can be evaluated by an increase in fluorescence.
Using the DNA binding dye PI, cells with compromised membranes can be
excluded. HL-60 cells treated with 10 µM Camptothecin for 4 h were used as
positive control.
Exponentially growing HL-60 cells were diluted in fresh cultivation medium
to 3.5× 105 cells/ml. The cell suspension was transferred to a sterile 6-well
Multidish to a total volume of 3 ml/well and resveratrol or vehicle was added
to obtain appropriate concentration (0.1 % vehicle). Cells were incubated
in the incubator for 18 h, and treated according to manufacturer’s protocol:
1× 106 cells were pelleted by centrifugation (400 g at 4 ◦C for 5 min), washed
twice with PBS. Cells were resuspended in 500 µl calcium containing Binding
Buffer. The cell suspensions were split to aliquots of 250 µl. One cell suspen-
sion received 5 µl Annexin-V-EGFP, the other 5 µl PBS. Both recieved 250 µl
calcium containing Binding Buffer, and were left to incubate for 15 min in the
dark at room temperature.
PI has a tendency to diffuse across the cell membrane, and therefore 5 µl
PI was added immediately prior to analysis. Stained cells were analysed as
described in ‘Flow cytometric parameters’ measuring Annexin-V and PI using
fluorescence intensity height, channel 1 (FL1-H) and fluorescence intensity
height, channel 3 (FL3-H), respectively. The FL3-H channel was to used to
minimise overflow from FL1-H.
The approximate excitation and emission peaks of EGFP are 488 nm and
530 nm and of DNA bound PI are 535 nm and 617 nm, respectively.
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2.6.4 Caspase-8 activity assessment
Activation of Caspase-8 was studied using the Vybrant FAM Caspase-8 Assay
Kit (Molecular Probes). The assay uses the membrane permeable irreversible
Caspase-8 inhibitor LETD-fmk. A carboxyfluorescein (FAM) group is linked
to the inhibitor peptide as a reporter.
Exponentially growing HL-60 cells were diluted in fresh cultivation medium
to 3.5× 105 cells/ml. The cell suspension was transferred to a sterile 6-well
Multidish to a total volume of 3 ml/well and resveratrol or vehicle was added
to obtain appropriate concentration (0.1 % vehicle). Cells were incubated in
the incubator for 12, 18, or 24 h, and treated according to manufacturer’s
protocol. Cells were diluted to 1× 106 cells/ml in fresh cultivation medium.
300 µl cell suspension was mixed with 10 µl 30× FAM-LETD-fmk, and left to
incubate in the dark for 60 min. After incubation cells were diluted in 1× wash
buffer, and pelleted by centrifugation (400 g at 4 ◦C for 5 min), and washed
twice in 1× wash buffer. Stained cells were analysed as described in ‘Flow
cytometric parameters’ using the FL1-H parameter.
The approximate excitation and emission peaks of the FAM are 488 nm
and 530 nm, respectively.
2.6.5 Flow cytometric parameters
All cells were analysed by flow cytometry on a FACSCalibur (Becton Dickin-
son) equipped with a standard 488 nm laser, and at least 20.000 events were
counted. The flow cytometer was controlled by the CellQuestPro version 4.0.2
(BD Biosciences) external software on Mac OS 9.
2.7 DAPI staining
To visualise changes in nuclear morphology, cells were stained with the DNA
binding dye DAPI and visualised with fluorescent microscopy. HL-60 cells
treated with 10 µM Camptothecin for 4 h were used as positive control.
Exponentially growing HL-60 cells were diluted in fresh cultivation medium
to 3.5× 105 cells/ml. The cell suspension was transferred to a sterile 6-well
Multidish to a total volume of 3 ml/well and resveratrol or vehicle was added
to obtain appropriate concentration (0.1 % vehicle). Cells were incubated in
the incubator for 12 or 18 h.
A stock solution of unit1mg /ml DAPI was made from DAPI dis-
solved in dH2O, and diluted to 1 µg/ml in PBS. 500 µl cell suspensions of
2× 105 cells/ml were spun onto coated glass slides (Thermo Electron) by
centrifugation at 1300 rpm at room temperature for 5 min using a Cytospin
4 Cytocentrifuge (Thermo Electron). The slides were left to dry completely
for at least 30 min to allow the cells to fully adhere. A hydrophobic barrier
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was drawn around the dried cells using a DakoCytomation Pen (DakoCy-
tomation). Cells were fixed with 4 % Paraformaldehyde in phosphate buffer,
pH 7.4 at room temperature for 15 min, and washed with cold PBS in a
Hellendahl-type staining jar (Bie & Berntsen) for approximately 3 min. Fixed
cells were permeabilised with ice cold 0.1 % Triton-X at room temperature
for 4 min, and washed twice with cold PBS. Permeabilised cells were stained
with 1 µg/ml DAPI in the dark at room temperature for 5 min and washed
once with cold PBS. Cover slips were mounted using Vectashield mounting
solution (Vector Labs). Stained cells were visualised on a Leica DMR light
microscope (Leica). Images of at least 6 random positions on the slide were
captured with a Leica DC200 camera (Leica), using the Leica IM50 version
1.20 release 19 (Leica) external software on Windows 2000.
2.8 Luciferase gene expression assay
The LucLite Reporter Gene Assay System (PerkinElmer) was used according
to manufacturer’s protocol.
Exponentially growing HeLa-pNF-kB-Luc cells were diluted in fresh cul-
tivation medium to 1.5× 105 cells/ml and transferred to sterile white 96-well
microtiter plate (PerkinElmer) to a total volume of 100 µl/well. All outer wells
received 100 µl PBS. Cells were placed in the incubator and allowed to ad-
here overnight. At the day of treatment, cultivation medium was removed by
carefully inverting the plates, and 100 µl assay medium containing resveratrol
with or without 5 ng/ml TNF-α or vehicle (0.1 %) was added to each well. All
outer wells received 100 µl PBS. The plates were left in the incubator for 4 h.
After incubation, medium was removed by carefully inverting the plates.
Working in subdued light conditions, 100 µl assay medium was added together
with 100 µl activated LucLite. The plates were sealed and incubated in the
dark at room temperature for 30 min. Luminescence was read in a TopCount
NXT luminescence counter (Packard). The TopCount NXT was controlled by
the TopCount NXT version 1.06 (Packard) external software on Windows 95.
2.9 Western blot analysis
2.9.1 Buffers and solutions
The following buffers and solutions were used for this analysis:
1× SDS-PAGE Sample Buffer 1/4 vol LDS 4× Sample Buffer, 1/10 vol
NuPAGE 10× Sample Reducing Agent, 1/100 vol Phosphatase Inhibitor Set II,
1/200 vol Protease Inhibitor Set III, and adjusted with dH2O
1× Chaps Cell Extract Buffer 1/10 vol 10× Chaps Cell Extract Buffer,
1/200 vol DTT, 1/200 vol Protease Inhibitor Set III, and adjusted with dH2O
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5 % BLOTTO 5 g nonfat dried milk diluted in 100 ml PBS with 0.1 %
Tween-20
5 % BSA 5 g BSA diluted in 100 ml PBS with 0.1 % Tween-20
2.9.2 Preparation of total cell lysate for immunoblotting anti-
Caspase-3 and anti-cleaved Caspase-3
Exponentially growing HL-60 cells were diluted to 4× 105 cells/ml in cultiva-
tion medium. The cell suspension was transferred to a sterile 6-well Multidish
to a total volume of 3 ml/well. Resveratrol or vehicle (0.1 %) was added, and
the plates were left in the incubator for 18 h.
After incubation, 1× 106 cells were diluted in as much cold PBS as possi-
ble, pelleted by centrifugation (400 g at 4 ◦C for 5 min), and the supernatant
was aspirated. Cells were washed once with cold PBS, transferred to Eppen-
dorf tubes. Cell lysis was performed by adding 100 µl 1× Chaps Cell Extract
Buffer. Cells were subjected to 3 cycles of freeze/thawing at -80 ◦C. Debris
was pelleted by centrifugation at 10000 g at 4 ◦C for 10 min in an Eppendorf
centrifuge and discarded. The supernatant was kept at -20 ◦C until used.
2.9.3 Preparation of total cell lysates for immunoblotting anti-
RelA/p65, or anti-phosphorylated RelA/p65 (Ser536)
Treatment and preparation of HeLa-pNF-kB-Luc cells Exponentially
growing HeLa-pNF-kB-Luc cells were diluted to 8.3× 104 cells/ml in cultiva-
tion medium. The cell suspension was transferred to sterile 6-well Multidishes
to a total volume of 3 ml/well and placed in the incubator and allowed to
adhere overnight.
At the day of treatment, medium was removed by gently inverting the
plates. 2 ml cultivation medium containing 5 ng/ml TNF-α with or without
resveratrol or vehicle (0.1 %) was added. The plates were left in the incubator
for the desired incubation time.
After incubation, medium was removed by gently inverting the plates and
cells were washed once with 37 ◦C PBS. Cell lysis was performed by adding
500 µl 2× SDS-PAGE Sample Buffer to each well. Cell lysate was transferred
to Eppendorf tubes and subjected to 3 cycles of freeze/thawing at -80 ◦C.
Debris was pelleted by centrifugation at 10000 g at 4 ◦C for 10 min in an
Eppendorf centrifuge and discarded. The supernatant was kept at -20 ◦C
until used.
Treatment and preparation of HL-60 cells Exponentially growing HL-
60 cells were diluted to 1× 106 cells/ml in cultivation medium. The cell sus-
pension was transferred to a sterile 6-well Multidish to a total volume of
2 ml/well. 5 ng/ml TNF-α with or without resveratrol or vehicle (0.1 %) was
added. The plates were left in the for the desired incubation time.
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After incubation, cells were diluted in as much cold PBS as possible, pel-
leted by centrifugation (400 g at 4 ◦C for 5 min) and the supernatant was
aspirated. Cell lysis was performed by adding 200 µl 1× SDS-PAGE Sample
Buffer. Cell lysates were transferred to Eppendorf tubes and subjected to 3
cycles of freeze/thawing at -80 ◦C. Debris was pelleted by centrifugation at
10000 g at 4 ◦C for 10 min in an Eppendorf centrifuge and discarded. The
supernatants were kept at -20 ◦C until used.
2.9.4 Immunoblotting with anti-Caspase-3, anti-cleavedCaspase-
3, anti-RelA/p65, or anti-phosphorylated RelA/p65
(Ser536)
Aliquots of 10 or 20 µl cell lysate were loaded and separated on 4-12 % gradient
SDS-PAGE gels (Invitrogen). 1× MES-SDS buffer was used as running buffer,
and 500 µl antioxidant was added to the top reservoir of the SDS-cell. A Full-
Range Rainbow Molecular Weight Markers (Amersham Biosciences) was used
as ladder.
Proteins were transferred to a PVDF membrane (Invitrogen) with a pore
size of 0.45 µm, using 1× Transfer buffer with 10 % methanol. Membranes
were blocked with 5 % BLOTTO for 1 h at room temperature or overnight
at 4 ◦C, and incubated overnight at 4 ◦C with anti-Caspase-3 (1/1000 dilution
in 5 % BLOTTO), anti-cleaved Caspase-3 (1/1000 dilution in 5 % BLOTTO),
anti-RelA/p65 (1/1000 dilution in 5 % BSA), or anti-phosphorylated RelA/p65
(Ser536) (1/1000 dilution in 5 % BSA).
A mix of anti-α-Tubulin (1/6000 dilution), anti-β-Actin (1/250,000 dilution),
and anti-GAPDH (1/100,000 dilution) all diluted in 5 % BLOTTO was used to
check proper loading. Membranes were incubated with the loading control
mix for 1 h at room temperature.
Blots were washed 6× for 10 min each with PBS with 0.1 % Tween-20
and incubated with peroxidase-labelled anti-rabbit IgG for 1 h at room tem-
perature. The bands labelled with the antibody were visualised using ECL
Advance chemiluminescent reagent (Amersham Biosciences) by exposure to a
LAS3000 CCD camera (Fujifilm), using the Image reader LAS3000 version 1.1
(Fujifilm) external software on Windows 2000.
Membranes were stripped for loading control by incubating with Restore
Western Blot Stripping Buffer on water bath for 60 to 80 min. Stripped mem-
branes were kept in PBS with 0.1 % Tween-20 until probing with the loading
control cocktail.
2.10 Software used
All calculations were performed using Microsoft Excel version 2002 SP-2
(Microsoft) and OpenOffice.org version 1.1.1 (OpenOffice.org). Flow cyto-
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metric data were prepared for presentation by Weasel version 2.1, unlicensed
(Walter and Eliza Hall Institute). CellQuestPro was utilised for the analysis
of cell size, while cell cycle distribution was analysed by ModFitLT version
2.0 (Verity Software House) for Mac OS 9. Band intensities of Western blots
were determined using Multi Gauge version 2.3 (Fujifilm) on Windows 2000.
Graphs and data fit was done by Grace the 5.1.x series on an appropriate
Linux system or Cygwin 1.5.11-1 and images were manipulated by The Gimp
version 2.0.x on an appropriate Linux system.
2.11 Calculations
All cells were counted by Brker haemocytometer, depth: 0.1 mm, area of
largest square: 0.04 mm2 (VWR International), and the cell density was cal-
culated by equation (2.1).
cells/ml =
cells counted× dilution factor× 104 squares/ml
number of squares counted
(2.1)
Relative thymidine incorporation, cell viability and relative relative lumines-
cence unit (RLU) was calculated by equation (2.2).
relative value =
meanresveratrol treated
meanvehicle treated
(2.2)
Relative band intensities was calculated by equation (2.3).
relative intensity =
intensityresveratrol treated
intensityvehicle treated
(2.3)
Relative RelA/p65 phosphorylation calculated by equation (2.4), the relative
intensities was found by equation (2.3).
relative phosphorylation =
relative intensityphosphorylated RelA/p65
relative intensitytotal RelA/p65
(2.4)
2.12 Statistical analysis
Statistical analysis were performed using Student’s two-tailed paired t-test.
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Chapter 3
Results
The purpose of this study was to identify the effects of resveratrol on:
• DNA synthesis – examined by the thymidine incorporation assay
• Cell cycle progression – evaluated by flow cytometric analysis of binding
of PI
• Apoptosis – assessed by DAPI staining, to visualise morphologic changes
of the cell nucleus, flow cytometric analysis of Annexin-V binding and
Caspase-8 activity, and Western blot using antibodies directed against
cleaved Caspase-3
• Phosphorylation of NF-κB – investigated by Western blot using anti-
bodies directed against phosphorylated RelA/p65.
Furthermore, the effect of fetal calf serum (FCS) on the levels of resveratrol,
as well as that of resveratrol on the size of cell nuclei was also studied.
3.1 DNA synthesis
To study the possible effect of resveratrol on DNA synthesis, the thymidine
incorporation assay was utilised, as described in ‘Materials and methods’, sec-
tion 2.3.
Resveratrol induces a dose dependent inhibition of thymidine in-
corporation in HL-60 cells When performing the concurrent resveratrol
addition variant of the thymidine incorporation assay, the concentration that
reduces the thymidine incorporation by 50 % (IC50) is altered in a time de-
pendent manner. IC50 increases from 5 µM resveratrol at 2 h to 20 µM resver-
atrol at 24 h (figure 3.1). No differences in IC50 values was observed between
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Figure 3.1: Resveratrol induces a time and dose dependent reduc-
tion in thymidine incorporation in HL-60 cells. Thymidine incorpo-
ration assay was utilised to study the effect of resveratrol on DNA synthesis
in HL-60 cells. Resveratrol was added to the cells concurrently, and cells
were harvested after the specified treatment times. Data is presented relative
to untreated cells. The experiment was performed on 6 occasions and re-
sults of a typical experiment are shown, and presented as mean ±SD, n = 6.
Overlapping data points are annotated with the lowest common p-value (**
represents p ≤ 0.01, *** represents p ≤ 0.001 compared to vehicle treated
cells)
2 and 4 h and between 24 and 48 h. This result indicates that resveratrol in-
hibits thymidine incorporation in a dose dependent manner, and that the IC50
increases as a function of time.
The effect of asynchronous addition of resveratrol to HL-60 cells
To study whether assay medium or cellular activity was the reason for the ob-
served effects on thymidine incorporation, the assay was modified as described
in ‘Materials and methods’, section 2.3.1.
When modifying the assay, no changes in IC50 values were observed from
2 to 12 h (figure 3.2), while IC50 values increased from 15 µM resveratrol at
12 h to 20 µM resveratrol at 24 and 48 h. The IC50 value at 24 and 48 h was
not affected by the described modification. This altered result, compared
to the result shown in figure 3.1, indicates that a reduction of active trans-
resveratrol occurs in a non-cellular dependent manner.
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Figure 3.2: Resveratrol induces a time and dose dependent reduc-
tion in thymidine incorporation in HL-60 cells. Thymidine incorpo-
ration assay was utilised to study the effect of resveratrol on DNA synthesis
in HL-60 cells. Resveratrol was added to cells at different time points, and
all cells were harvested at the same time after the specified treatment times.
Data is presented relative to untreated cells. The experiment was performed
on 5 occasions and results of a typical experiment are shown, and presented
as mean ±SD, n = 6. Overlapping data points are annotated with the lowest
common p-value (** represents p ≤ 0.01, *** represents p ≤ 0.001 compared
to vehicle treated cells)
Taken together, the results presented in figure 3.1 and figure 3.2 indicate,
that resveratrol inhibits incorporation of thymidine in HL-60 cells in a dose
dependent manner, and that levels of active trans-resveratrol may be dimin-
ished in cell cultivation medium. The latter is examined in further detail in
section 3.2.
Resveratrol induces a time and dose dependent reduction in in-
corporation of thymidine in HepG2 cells When treated with resvera-
trol asynchronously, an increase in IC50 values of thymidine incorporation in
HepG2 cells was observed (figure 3.3). The IC50 values ranged from 15 µM at
2 h to 50 µM at 12-24 h (3.3a), and finally decreased to 35 µM at 48 and 72 h
(3.3b). This indicates that the modification of the IC50 value is a function of
resveratrol dose and incubation time, when incubation time is less than 24 h.
For incubation times greater than 24 h IC50 is modified as a function of dose
and an inverse function of time in HepG2 cells.
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(a) Treatment for 2 to 24 h
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(b) Treatment for 24 to 72 h
Figure 3.3: Resveratrol induces a time and dose dependent reduc-
tion in thymidine incorporation in HepG2 cells. Thymidine incorpo-
ration assay was utilised to study the effect of resveratrol on DNA synthesis
in HepG2 cells. Resveratrol was added to the cells asynchronously, and cells
were harvested after the specified treatment times. To clarify the difference
in time dependency, the results from the same experiment are split into 2 to
24 h (a) and 24 to 72 h (b). Data is presented relative to untreated cells. The
experiment was performed on 3 occasions and results of a typical experiment
are shown, and presented as mean ±SD, n = 6. Overlapping data points
are annotated with the lowest common p-value (** represents p ≤ 0.01, ***
represents p ≤ 0.001 compared to vehicle treated cells)
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(a) 80 µM resveratrol in PBS
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(b) 80 µM resveratrol in PBS+FCS
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Figure 3.4: FCS stimulates reduction of trans-resveratrol as a func-
tion of time. Absorption spectra of 80 µM resveratrol, corrected for back-
ground. Resveratrol was diluted in PBS alone (a) or in PBS with 10 % FCS
(b) and incubated in a standard incubator. At the specified times aliquots
of 100 µL was passed to a UV-transparent 96-well microtiter plate, and an
absorption scan was performed. The result of a single experiment is pre-
sented as mean, n = 3. (c) the absorbance at OD310 of 80 µM resveratrol as
a function of time and FCS concentration. Data is fitted to y = A×xB . The
result of a single experiment is presented as mean ±SD, n = 3
3.2 Light-absorption scan
To further elucidate the role of cell cultivation medium on the apparent re-
duction in the levels of trans-resveratrol, resveratrol was diluted in PBS with
or without FCS.
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Presence of serum stimulates reduction in the levels of trans-
resveratrol The absorption spectrum of resveratrol was obtained as de-
scribed in ‘Materials and methods’, section 2.4. When diluted in PBS alone,
the absorption spectrum of 80 µM was maintained for 7 days (figure 3.4a).
The absorption spectrum of resveratrol diluted in PBS with 10 % FCS was
clearly reduced as a function of time (figure 3.4b) by almost 33 % after 24 h
and 50 % after 48 h. Using standard universal pH indicators, no changes in
pH were found (data not shown)
In summary, this indicates that levels of resveratrol is constant when di-
luted in PBS alone, while the presence of 10 % FCS reduces the level of resver-
atrol.
The degree of reduction of trans-resveratrol is correlated to the levels
of FCS (figure 3.4c). 5 % FCS stimulates reduction of the levels of trans-
resveratrol to a lesser extent than 10 and 20 % FCS.
The absorption spectra shown in figure 3.4 were obtained for 80 µM resver-
atrol. Similar results were obtained for 40 µM resveratrol, and the difference
in absolute absorption reflects the difference in resveratrol concentration (data
not shown). The result obtained at 3 days is considered flawed.
Notation of resveratrol concentrations To avoid confusion between
resveratrol concentrations used in this report and values stated by others, all
resveratrol levels mentioned are added start concentrations.
3.3 Interference with common cytotoxicity assays
To further study the effects of resveratrol on cell proliferation, we turn to other
assays to gain insight into the cytotoxicity of resveratrol on HL-60 and HepG2
cells.
Resveratrol interferes with the MTT assay The MTT assay is com-
monly used to asses cytoxicity of a compound and was performed as described
in ‘Materials and methods’, section 2.5.1. Based on the data obtained by the
thymidine incorporation assay, it was expected that a cytotoxic effect could
be measured using the MTT assay. However, when treating HepG2 cells with
resveratrol, the assay fails to produce statistically significant data (figure 3.5a).
The assay itself was demonstrated in the present work to be reliable by
reproducing the results of Hill et al. (1995) and Yoshikawa et al. (1999) (fig-
ure 3.5b): TNF-α together with Actinomycin-D, but not alone stimulated cell
death in HepG2 cells. There was no significant increase in cell death, when
HepG2 cells were treated with TNF-α alone for up to 72 h. Co-treatment
with TNF-α and Actinomycin-D reduced the viability of HepG2 cells after
24 h. Actinomycin-D alone significantly reduced viability after 48 and 72 h,
and the reduction was further enhanced by co-treatment with TNF-α.
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Figure 3.5: Resveratrol interferes with the result of the MTT assay.
HepG2 cells were treated with test compound and viability was determined
at the specified times by the MTT assay. Cells were treated with resveratrol
(a). The experiment was performed on 6 occasions and results of a typical
experiment are shown, and presented as mean ±SD, n = 6. Cells were treated
with TNF-α with or without 0.5 µg/ml Actinomycin-D (b). The experiment
was performed on 3 occasions and results of a typical experiment are shown,
and presented as mean ±SD, n = 6. Data is presented relative to untreated
cells. Overlapping data points are annotated with the lowest common p-value
(** represents p ≤ 0.01, *** represents p ≤ 0.001 compared to vehicle treated
cells)
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Figure 3.6: Resveratrol interferes with the result of the NR assay.
HL-60 cells were treated with various concentrations of resveratrol and via-
bility was determined at the specified times by the NR assay. The result of a
single experiment is presented as mean ±SD, n = 6 (** represents p ≤ 0.01,
*** represents p ≤ 0.001 compared to vehicle treated cells)
Taken together, these results indicate that in my hands resveratrol may
interfere with the result on the MTT assay.
Resveratrol interferes with the NR assay To overcome the problems
observed in the MTT assay, a different assay was chosen. The NR assay is
based on active dye uptake by viable cells, as described in ‘Materials and meth-
ods’, section 2.5.2. The uptake of NR dye was an unreliable measurement of
the viability of resveratrol treated HL-60 cells (figure 3.6), with large standard
deviations and only few measurements with significance less than 5 % com-
pared to vehicle treated cells. This demonstrates that resveratrol interferes
with the NR assay.
3.4 Cell cycle progression
To further explore the effects of resveratrol induced inhibition of cell growth
measured by thymidine incorporation, the cell cycle modulating properties of
resveratrol were examined. These experiments were performed as described in
‘Materials and methods’, section 2.6.1.
Resveratrol induces cell cycle arrest in HL-60 cells After treatment
with resveratrol for 24 h, there was a clear dose dependent induction of cell cy-
cle accumulation (figure 3.7). At low doses (20 µM) the number of HL-60 cells
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(a) Vehicle (b) 20 µM resveratrol
(c) 40 µM resveratrol (d) 80 µM resveratrol
Figure 3.7: Resveratrol induces cell cycle arrest in HL-60 cells.
Cells were treated with vehicle (a), 20 (b), 40 (c), or 80 µM (d) resveratrol
for 24 h and the cell membrane was removed. The nuclei were stained with
PI and the DNA content was examined by flow cytometry. Data is presented
as cell count as a function of DNA content. The results are summarised in
figure 3.8.
in the S phase were clearly increased. At increased resveratrol concentrations
(40 and 80 µM) the cell cycle was affected in the G1 phase.
Resveratrol induces cell cycle arrest in HepG2 cells The effect on
cell cycle progression in HepG2 cells (figure 3.9), appeared to follow the same
pattern as was observed with HL-60 cells. Incubation with 20 µM resveratrol
for 24 h had no effect on the cell cycle distribution, while 40 µM increased
the number of cells in the S phase. At increased concentrations (80 µM),
resveratrol also caused accumulation of cells in the S phase, but to a lesser
extent than was observed for 40 µM.
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Figure 3.8: Summary of the cell cycle modulating effect of resver-
atrol in HL-60 cells. The results of figure 3.7 are summarised. Data is
presented as relative phase distribution. The experiment was performed on
3 occasions and results of a typical experiment are shown, and presented as
mean ±SD, n = 3. Overlapping data points are annotated with the lowest
common p-value (** represents p ≤ 0.01, *** represents p ≤ 0.001 compared
to vehicle treated cells)
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Figure 3.9: Resveratrol induces cell cycle arrest in HepG2 cells.
Cells were treated with vehicle or 20, 40, or 80 µM resveratrol for 24 h. The
nuclei were stained with PI and the DNA content was examined by flow
cytometry. Data is presented as relative phase distribution. The experiment
was performed on 3 occasions and results of a typical experiment are shown
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(a) Vehicle (b) 20 µM resveratrol
(c) 40 µM resveratrol (d) 80 µM resveratrol
Figure 3.10: Resveratrol stimulates an increase in the nuclear size
in HL-60 cells. Cells were treated with vehicle (a), 20 (b), 40 (c), or
80 µM (d) resveratrol for 24 h and the cell membrane was removed. Nuclei
were stained with PI and the DNA content examined by flow cytometry.
Data is presented as contour plots of DNA content (FL2-H) as a function
of nucleus size FSC-H. Cell number is represented as iso-lines. The sub-G1
population of dead cells is visible in the lower left corner. The experiment
was performed on 3 occasions and results of a typical experiment are shown
These two results demonstrate that resveratrol modulates the cell cycle in
vitro. The phase affected by resveratrol treatment depends on the concentra-
tion used.
3.5 Modulation of the size of cell nuclei
The effect of resveratrol on the size of HL-60 cell nuclei was studied as described
in ‘Materials and methods’, section 2.6.1. Based on the observations of the cell
cycle modulating effects of resveratrol, an increase in the size of the nucleus was
expected only for HL-60 cells treated with 20 µM resveratrol, and HepG2 cells
treated with 40 µM resveratrol. The reasoning was that these concentrations
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Figure 3.11: Resveratrol stimulates an increase in granularity but
does not alter cell size in HL-60 cells. Cells were treated with vehicle
or 20, 30, 40 or 80 µM resveratrol for 24 h. The size (FSC-H; left axis) and
granularity (SSC-H; right axis) of the cells was examined by flow cytometry.
The experiment was performed on 3 occasions and results of a typical ex-
periment are shown, and presented as mean ±SD, n = 3. Data points not
sharing a letter are significantly different (p ≤ 0.001)
stimulated S phase accumulation of cells, while increased doses stimulated
accumulation in the G1 phase of the two cell lines.
Resveratrol stimulates an increase of the size of HL-60 nucleus
Modulation of cell cycle progression of HL-60 cells caused by resveratrol was
correlated with an increase in the size of the nucleus (figure 3.10). This corre-
lation of the nucleus size and the cell cycle phase was possible to evaluate as
cellular membranes were removed by the use of the non-ionic detergent. It is
predominantly cells in the G1 phase which display enlarged nuclei, but other
stages of the cell cycle are also affected. The observation derives from study-
ing the iso-lines of the contour plots of figure 3.10 as a function of particle
size (FSC-H) and bound PI (FL2-H). A putative sub-G1 population of dead
cells is visible in the lower left corner. An increase in size of nucleus was not
observed in HepG2 cells (data not shown).
These results indicate that resveratrol stimulates an increase in the nuclear
size of HL-60 cells.
Increase in nucleus is not accompanied by an increased cell size To
examine whether the increase in the size of the nucleus was paralleled by an
increase in the volume of the cell, HL-60 cells were treated with resveratrol for
24 h and analysed by flow cytometry, as described in ‘Materials and methods’,
section 2.6.2. It was demonstrated that resveratrol had no effect on cell size
of HL-60 cells as indicated by the median of the forward scatter (figure 3.11).
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(a) Vehicle (b) 20 µM resveratrol
(c) 40 µM resveratrol (d) 10 µM camptothecin
Figure 3.12: Resveratrol stimulates morphological changes of the
cell nucleus of HL-60 in a dose dependent manner. Cells were treated
with vehicle (a), 20 µM (b), or 40 µM (c) resveratrol for 18 h. After treat-
ment, cells were stained with DAPI and the nuclei visualised under a fluo-
rescence microscope. 10 µM camptothecin (d) (4 h incubation) was used as
positive control. Morphological changes are indicated by white arrowheads.
The experiment was performed on 4 occasions and results of a typical exper-
iment are shown
Resveratrol induces an increase in cell granularity of HL-60 cells
Low doses of resveratrol (20 µM) induced a larger granularity (i.e. altered
the amount and/or type of cytoplasmic granules) in HL-60 cells, as measured
by the median of the SSC-H, compared to control cells (figure 3.11). Higher
doses counteracted the increase in granularity to a minor yet significant degree
compared to that of 20 µM resveratrol.
These results demonstrate that the observed increase in nucleus size of HL-
60 does not correlate to an increase in cell size. However, resveratrol stimulates
an increase in cellular granularity in a dose dependent manner.
3.6 Apoptosis
With the aim of studying the effect of resveratrol on apoptosis in HL-60 cells,
several assays were applied. It was found that resveratrol stimulated condensa-
tion and fragmentation of the cell nucleus, increased the binding of Annexin-
V, and stimulated cleavage of Procaspase-3 and stimulated the activity of
Caspase-8.
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(a) Vehicle (b) 20 µM resveratrol
(c) 30 µM resveratrol (d) 40 µM resveratrol
(e) 80 µM resveratrol
Figure 3.13: Resveratrol stimulates an increase in Annexin-V bind-
ing in a dose dependent manner in HL-60 cells. Cells were treated
with vehicle (a), 20 (b), 30 (c), 40 (d), or 80 µM (e) resveratrol for 18 h.
After resveratrol treatment, cells were double stained with Annexin-V and
PI, and examined by flow cytometry. Data is presented as PI (FL3-H) ver-
sus Annexin-V-EGFP (FL1-H), with the numbers indicating the percentage
of cells in each quadrant. The experiment was performed on 3 occasions
and results of a typical experiment are shown. The data are summarized in
figure 3.14
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Figure 3.14: Resveratrol stimulates an increase in Annexin-V bind-
ing in a dose dependent manner. Graphical representation of the results
in figure 3.13. Data is presented relative to untreated cells. The experiment
was performed on 3 occasions and results of a typical experiment are shown,
and presented as mean ±SD, n = 3 (** represents p ≤ 0.01, *** represents
p ≤ 0.001 compared to vehicle treated cells)
Resveratrol induces changes in nuclear morphology The ability of
resveratrol to modulate apoptosis was initially studied by examining nuclear
morphological changes associated with apoptosis as described in ‘Materials and
methods’, section 2.7. In a preliminary study, the optimal incubation time of
HL-60 cells with resveratrol was found to be 12 to 18 h (data not shown).
When treated with resveratrol for 18 h, there was an obvious dose dependent
increase in the number of HL-60 nuclei with a condensed and fragmented
morphology (figure 3.12). This demonstrates a dose-dependent stimulation of
apoptotis by resveratrol.
Binding of Annexin-V increases with increasing resveratrol concen-
tration To further study the apoptosis modulating effect in HL-60 cells by
resveratrol, the Annexin-V binding assay was applied as described in ‘Materi-
als and methods’, section 2.6.3. Figure 3.13 shows the result of flow cytometric
analysis of binding of EGFP conjugated Annexin-V. These results are sum-
marised in figure 3.14. Apoptotic cells in this assay binds Annexin-V but
exclude the nuclear binding dye PI, i.e. cells with lost membrane asymmetry
but intact membranes.
HL-60 cells treated with resveratrol for 18 h showed a concentration de-
pendent increase in Annexin-V positive/PI negative cells (figure 3.13). Loss
of membrane integrity occurred as a function of resveratrol concentration at
the same rate as Annexin-V positive only cells.
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Figure 3.15: Resveratrol stimulates cleavage of Procaspase-3 in
HL-60 cells. Cells were treated with specified resveratrol concentrations
for 18 h and prepared for Western blot. The controls were Jurkat cells with
(+) or without (–) treatment with Cytochrome c and were provided with the
antibodies. Immobilised protein was probed with anti-Procaspase-3 (a) or
anti-cleaved Caspase-3 (b), where cell lysate was loaded twice to the same
SDS-PAGE gel. The amount of antigen was analysed by density measure-
ments of bands and is summarised in figure 3.16
As shown in figure 3.14 only a minor effect of 20 µM resveratrol on HL-
60 cells was found, while higher concentrations greatly stimulated Annexin-V
binding and membrane permeability.
Resveratrol stimulates Caspase-3 cleavage in a dose dependent fash-
ion The observed changes in nuclear morphology and increased binding of
Annexin-V suggest involvement of Caspase-3 in resveratrol stimulated apopto-
sis. Western blot detecting cleaved Caspase-3 was applied to study the effect of
resveratrol on cleavage of Caspase-3 as described in ‘Materials and methods’,
section 2.9. Resveratrol had no significant effect on the levels of Procaspase-3
(figure 3.15a), but exerted a stimulating effect on cleavage of Procaspase-3 into
the larger and smaller catalytic subunits of 17 and 12 kDa (figure 3.15b).
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Figure 3.16: Summary of resveratrol stimulated cleavage of
Caspase-3 in HL-60 cells. The amount of antigen shown in figure 3.15
was analysed by density measurements of the bands. Caspase-3 cleavage is
expressed in relative values with vehicle controls arbitrarily set as 1. The
experiment was performed on 3 occasions and results of a typical experiment
are shown
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Figure 3.17: Resveratrol stimulates Caspase-8 activity in HL-60 in
a dose and time dependent manner. Cells were treated with resveratrol
for 18 (a) and 24 h (b), incubated with FAM labelled Caspase-8 inhibitor,
and analysed by flow cytometry. Data is presented as counts as a function
of fluorochrome bound to Caspase-8. The result of a single experiment is
shown.
Legend: Gray area is cells treated with vehicle, dotted line is 20 µM, and full
line is 80 µM resveratrol
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Negligible effect of 20 µM resveratrol on the levels of catalytic Caspase-
3 subunits was observed, while higher concentrations of resveratrol clearly
stimulated cleavage of Procaspase-3 (figure 3.16).
Resveratrol stimulates Caspase-8 activity To study the involvement
of the extrinsic pathway in the apoptosis modulating effects of resveratrol,
Caspase-8 activity was assayed by flow cytometry as described in ‘Materials
and methods’, section 2.6.4. In a preliminary study incubation with resveratrol
for 18 h (figure 3.17a) and 24 h (figure 3.17b) showed a stimulated binding of
a specific Caspase-8 inhibitor labelled with the FAM fluorophor. This binding
was increased with increased resveratrol concentration and longer incubation
time. Thus an increased Caspase-8 activity as a function of resveratrol con-
centration and treatment time can be observed.
3.7 Phosphorylation of NF-κB
The possible role of NF-κB in the stimulation of apoptosis by resveratrol was
studied. It was found that resveratrol modulated the product of a NF-κB
controlled reporter gene in HeLa-pNF-kB-Luc cells. It was also found that
resveratrol does not modulate the phosphorylation of NF-κB in HL-60 cells as
studied by the use of Western blot for phosphorylated RelA/p65.
Resveratrol reduces levels of NF-κB controlled luciferase gene prod-
uct HeLa-pNF-kB-Luc cells are HeLa cells stably transfected with a lu-
ciferase reporter gene under the transcriptional control of the NF-κB promoter.
The luciferase gene expression assay was performed as described in ‘Materials
and methods’, section 2.8.
It was found that 5 ng/ml tumor necrosis factor (TNF-α) induced more
than 60 fold increase in luciferase products (data not shown). The effect of
resveratrol on TNF-α induced luciferase product was subsequently examined
(figure 3.18). Resveratrol was capable of reducing the levels of luciferase prod-
uct (figure 3.18a), with an IC50 value of 10 µM in both TNF-α stimulated and
unstimulated cells, as measured by RLU. However, when co-treated with
TNF-α, the inhibitory effect of resveratrol was 40 fold, compared to a 10 fold
inhibition of unstimulated cells (figure 3.18b). Preincubation with resveratrol
for 4 h did not enhance the effect (data not shown).
RelA/p65 is rapidly phosphorylated and dephosphorylated in HL-60
and HeLa-pNF-kB-Luc cells To establish the time curve of TNF-α stim-
ulated RelA/p65 phosphorylation in HL-60, cells were treated with 5 ng/ml
TNF-α for various durations between 0 and 4 h, and submitted to Western
blot for anti-RelA/p65 and anti-phosphorylated RelA/p65, with HeLa-pNF-
kB-Luc as a positive control (figure 3.19).
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Figure 3.18: Resveratrol inhibits TNF-α stimulated transcription
of the luciferase gene in HeLa-pNF-kB-Luc cells. Cells were treated
with specified concentrations of resveratrol, or vehicle alone in the presence
or absence of 0.5 ng/ml TNF-α. Levels of expressed luciferase gene was
examined by luminescence. Data is presented as RLU relative to untreated
cells (a) and RLU (b). The experiment was performed on 3 occasions and
results of a typical experiment are shown, and presented as mean ±SD, n = 3.
Overlapping data points are annotated with the lowest common p-value (**
represents p ≤ 0.01 compared to vehicle treated cells)
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Figure 3.19: TNF-α stimulates rapid and transient phosphorylation
of RelA/p65 in HeLa-pNF-kB-Luc and HL-60 cells. HL-60 (a) and
HeLa-pNF-kB-Luc (b) cells were treated with 5 ng/ml TNF-α for the spec-
ified times and prepared for Western blot. Immobilised protein was probed
with anti-RelA/p65 or anti phosphorylated RelA/p65. The result of a single
experiment is shown
Phosphorylation of RelA/p65 in HL-60 cells RelA/p65 appears to
exist mainly in a truncated form of 55 kDa in HL-60 cells (figure 3.19a). Total
levels of both the 65 kDa and 55 kDa fragments declined between 3 and 4 h
after addition of 5 ng/ml TNF-α. Both fragments had low background levels
of RelA/p65 phosphorylation. The phosphorylation of both fragments peaked
after 10 min with TNF-α and then declined over the course of 4 h after 30 min.
Phosphorylation of RelA/p65 in HeLa-pNF-kB-Luc cells The
TNF-α stimulated RelA/p65 phosphorylation reaches maximum levels in
HeLa-pNF-kB-Luc cells 10 min after addition of the ligand (figure 3.19b).
The background levels of RelA/p65 phosphorylation are easily detectable,
and the level is slightly increased after stimulation with 5 ng/ml TNF-α for
4 h.
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Figure 3.20: Resveratrol has no effect on TNF-α stimulated
RelA/p65-phosphorylation in HL-60 cells. Cells were treated with
vehicle or 20 or 80 µM resveratrol for the specified times in the presence
of 5 ng/ml TNF-α and prepared for Western blot. Immobilised protein from
HL-60 cells was probed with anti-RelA/p65 or anti-phosphorylated RelA/p65
(a). The experiment was performed on 4 occasions and results of a typical
experiment are shown Immobilised protein from HeLa-pNF-kB-Luc cells was
probed with anti-RelA/p65 or anti-phosphorylated RelA/p65 (b). The ex-
periment was performed on 2 occasions and results of a typical experiment
are shown, and summarised in (c), where data is presented as fold induction
of phosphorylation relative to cells treated for 0 h. Relative phosphorylation
is determined as the relative phosphorylation compared to untreated over
relative levels of total RelA/p65 compared to untreated
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Resveratrol does not inhibit phosphorylation of RelA/p65 in HL-
60 cells The focus for this part of the present study was to evaluate the
immediate effect of resveratrol on phosphorylation of RelA/p65. Neither for
the 65 kDa nor the 55 kDa fragment, was an effect of resveratrol on TNF-α
stimulated RelA/p65 phosphorylation observed (figure 3.20a).
As a positive control, TNF-α stimulated RelA/p65 phosphorylation
in HeLa-pNF-kB-Luc was studied (figure 3.20b and summarised in fig-
ure 3.20c). Resveratrol seemed to limited the TNF-α induced phosphorylation
of RelA/p65 in a dose dependent manner and at all measured time points.
3.8 Summary
In summary the following results regarding the effects of resveratrol were ob-
tained:
DNA synthesis Even low concentrations and short treatment times inhib-
ited DNA synthesis
Cell cycle progression The phase affected depended on the resveratrol con-
centration used
Apoptosis Resveratrol stimulated apoptosis in a dose dependent manner,
with Caspase-3 activation. The extrinsic pathway was also activated
Activation of NF-κB No inhibitory effect on phosphorylation of the 65 or
55 kDa RelA/p65 fragment in HL-60
Furthermore, it was found that levels of resveratrol decreased over time in the
presence of FCS. Resveratrol stimulated an increase in the nuclear size, which
was not paralleled by an increase in cell size.
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Chapter 4
Discussion and conclusion
4.1 Purpose
The purpose of this study was to identify the effect of resveratrol on DNA
synthesis and cell cycle progression. The apoptosis stimulating properties of
resveratrol were also studied, as well as the possible role of NF-κB in cell cycle
modulation and apoptosis.
4.2 Inhibition of thymidine incorporation
The dose dependent effect on cell growth measured by thymidine incorporation
after 2 h was a very surprising and most interesting observation. To the best of
my knowledge, this is the first report to show that short term treatment with
low concentrations of resveratrol affects the growth of HL-60 and HepG2 cells
in culture. The observation has only been paralleled by observations in the
human prostate cancer cell line LNCap (Kuwajerwala et al., 2002). Because
of lack of detailed description of experimental procedures, it is impossible
to compare the IC50 value reported by Kuwajerwala et al. (2002) with those
observed in the present study. The IC50 value at 24 and 48 h is in concordance
with what has been reported earlier (Horvath et al., 2005; Roy et al., 2002).
In HL-60 cells, an IC50 value of 20 µM has been reported after treatment
for 8 h (Surh et al., 1999).This value is in agreement with the results obtained
in this study of 15 µM. The observed IC50 value in HepG2 is in disagreement
with observations made by Delmas et al. (2000), who observed no decrease
in incorporation of thymidine. The difference may be due to different experi-
mental conditions.
The reduced proliferation rate of HL-60 and HepG2 cells after short time
incubation, could indicate interference with the replication machinery. This
interference may be a direct or a indirect inhibition of formation or move-
ment of the DNA polymerase. Resveratrol has been shown to interfere with
the DNA polymerase (Stivala et al., 2001; Sun et al., 1998) and inhibit the
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ribonucleotide reductase (Fontecave et al., 1998; Pozo-Guisado et al., 2002).
In full concordance, resveratrol has been shown to reduce intracellular levels
of dNTPs in HL-60 cells (Horvath et al., 2005). Although treatment with
resveratrol for 24 h has no effect on assembly of replication complexes (Stivala
et al., 2001), it cannot be ruled out as an immediate effect. The mechanism
by which resveratrol inhibits synthesis of DNA is not yet fully understood, but
may depend on the DNA polymerase involved (Stivala et al., 2001).
The effect of resveratrol on thymidine incorporation in HepG2 cells pre-
sented here, is in disagreement with observations made by Goldberg et al.
(1995a). The authors observed no inhibition of DNA synthesis or viability,
when HepG2 cells were treated with 1, 5, or 50 µM resveratrol for 1, 3, and
7 days. This discrepancy is yet unexplained.
In conclusion, short term treatment with resveratrol results in a
straight forward dose dependent interference with the cell proliferation. This
effect of resveratrol is previously unreported.
4.3 Stability of resveratrol
When HL-60 cells were treated with resveratrol and incorporation of thymidine
was measured, the IC50 value for growth inhibition increased as a function
of incubation time (figure 3.1). This increase could be explained by the cells
causing detoxification of resveratrol. Such a detoxification of resveratrol would
be expected to require gene activation. The fact that IC50 increased between
4 to 24 h, but not between 2 and 4 h suggests the need for activation of a set of
genes and thus supports the idea of detoxification. However, treatment for 8 h
may not be enough time for gene activation alone to account for the observed
effect. This indicates some additional effect e.g. degradation or inactivation
of trans-resveratrol as the cause of the observed increase in IC50 values.
Resveratrol is labile as a result of an extracellular effect To evalu-
ate whether the cells were actively involved in the observed increase in IC50
values the thymidine incorporation assay was modified from concurrent to
asynchronous resveratrol addition, as described in ‘Materials and methods’,
section 2.3.1. The reasoning being that if cellular activity e.g. metabolism
was needed for the increase in IC50 values the increase would not be affected
by the modified assay. If, on the other hand, the increase was due to degrada-
tion or inactivation of resveratrol in the medium a reduced difference in IC50
values would be expected.
As shown in figure 3.2 the actual outcome of the experiment was a collapse
of all IC50 values into a single value. This result, clearly demonstrates that
the observed increase in IC50 values is related to an extracellular effect.
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FCS is associated with reduction in levels of trans-resveratrol Light
absorption was used as a method to determine levels of resveratrol in solutions.
This method is possible, because trans-resveratrol has a distinct absorption
spectrum with an absorption maximum of approximately 308 nm (Trela and
Waterhouse, 1996).
To analyse if the decreased levels of active trans-resveratrol was caused by
FCS in the media, resveratrol was diluted in PBS with (figure 3.4b) or without
(figure 3.4a) FCS. When diluted in PBS alone and left in centrifugation tubes
in the dark in a standard incubator, resveratrol was stable and concentrations
retained for at least 7 days. This clearly rules out any adsorption to the plastic
of the tube.
It can, however, be observed from the result in figure 3.4 that the presence
of FCS causes the absorption at 310 nm to be reduced with time. This demon-
strates for the first time that trans-resveratrol in a FCS containing solution
disappears as a function of time.
The result presented in figure 3.4c shows that an increase in FCS from
10 to 20 % has little effect on levels of reduction in absorbance, indicating
that some maximum has been reached at 10 % FCS. In support of this, 5 %
FCS has a lesser effect on the levels of resveratrol than 10 % FCS. However,
the light-absorption scan is a semiqualitative method, and only tendencies
can be extracted. To further study the degradation of resveratrol in solution,
analysis by HPLC would be appropiate. This would give valuable information
on specific resveratrol quantities in solution as well as possible metabolites
formed.
Enzymatic activity of compounds of FCS can be ruled out as a cause of the
reduction, since the FCS used was heat inactivated. Resveratrol has previously
been shown to bind to BSA (Jannin et al., 2004; Lanc¸on et al., 2004), thus
direct interaction with other proteins of the FCS is a likely event. Binding to
proteins in the FCS could affect resveratrol in several possible ways. 1) The
compound of FCS which binds resveratrol in turn might adsorb to the plastic
of the tube. However, this does not explain the observed tail in the visible
light range. 2) Binding of resveratrol to some component of FCS could change
the light-absorption of resveratrol. The absorption of resveratrol bound to
a compound must then shift towards the visual range to accommodate the
observed tail.
The role of cellular activity When HepG2 cells were treated with resver-
atrol an increase in IC50 value of incorporated thymidine was observed from
2 to 24 h (figure 3.3). This strongly suggests the role of cellular activity e.g.
metabolism in addition to the effect of FCS. Given the fast increase in IC50
values between 2 and 4 h, the cellular activity may not require gene activation.
Metabolism of resveratrol in HepG2 cells is not well studied. It has been
shown that resveratrol stimulated expression of the Cyp1A1 gene (Allen et al.,
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2001), while no effect on the expression of the Cyp3A4 gene has been observed
(Raucy, 2003).
Glucuronidation of resveratrol has been observed in human liver sam-
ples (Santi et al., 2000a), and HepG2 cells has furthermore been shown to
metabolise quercetin, another polyphenol, to quercetin glucuronide (O’Leary
et al., 2003). It is therefore possible that some cells actively inactivate resver-
atrol by metabolism.
In conclusion, FCS stimulates a reduction in the levels of trans-resveratrol,
an effect previously unreported. In addition cellular activity in some cell lines
may also contribute to the reduction. Further studies with HPLC or other
more discriminative methods are needed to asses the rate of reduction and
production of possible metabolites.
4.4 The effect on the cell cycle
A striking result of treating HL-60 and HepG2 cells with different concentra-
tions of resveratrol, is the dose dependent phase specific accumulation of cells
(figures 3.8 and 3.9).
20 µM resveratrol for 24 h resulted in nearly a doubling of the number of
cells in the S phase compared to untreated HL-60 cells. The same was observed
for 40 µM in HepG2 cells. The result presented here demonstrates that low
levels of resveratrol prolong the S phase.
Is has been suggested that the accumulation of cells in the S phase shows
a stimulatory effect of low levels of resveratrol on DNA synthesis (Dorai and
Aggarwal, 2004). However, the only valid explanation of the accumulation of
cells in the S phase is that the phase is prolonged.
Treatment with 80 µM doubles the number of cells in the G1 phase com-
pared to HL-60 and HepG2 cells treated with 20 and 40 µM, respectively. This
result clearly suggests that high levels of resveratrol stimulate accumulation of
HL-60 cells in the G1 phase and thus prevent cells from entering the S phase.
This view is in concordance with observations where resveratrol inhibited pro-
duction of polyamines by interfering with the Ornithine Decarboxylase (ODC)
(Schneider et al., 2000). Polyamines are found in all studied eucaryotic cells
and are heavily involved in cell progression to the S phase. The rate limit-
ing step in polyamine production is catalysed by ODC (Wolter et al., 2004).
Resveratrol is cabable of preventing entry into the S phase.
The result obtained for HepG2, where the dose dependent phase specific
accumulation of cells is less pronounced, may in part be explained by some
cellular detoxification activity of the HepG2 cells, as discussed in section 4.3.
The hypothesis of a dose dependent cell cycle arrest in HL-60 and HepG2
cells is in agreement with what has been observed in a range of other cell
lines (Bernhard et al., 2000; Delmas et al., 2002; Kuwajerwala et al., 2002;
75
Matsuoka et al., 2001; Opipari et al., 2004; Pozo-Guisado et al., 2002; Stivala
et al., 2001; Wolter et al., 2001), see table 1.4.
The G1 phase accumulation of HL-60 cells observed in the present study
is in agreement with findings reported by Kang et al. (2003), who found that
100 µM resveratrol for 24 h stimulated an accumulation of HL-60 cells in the
G1 phase. This result is in disagreement with an earlier report by Joe et al.
(2002). The authors found that 300 µM resveratrol for 24 h stimulated an
accumulation of cells in the S phase. However, the resveratrol concentration
used by Joe et al. was so high that a direct comparison is difficult.
The cell cycle analysis explain the reduced cell growth at 24 h, but does
not reveal if there is a dose dependent slowdown of cell cycle progression or a
dose dependent cell cycle arrest point. Cells caught in an extended S phase
may initiate the process of apoptosis. However, to the best of my knowledge,
no report yet has shown cell cycle phase specific stimulation of apoptosis by
resveratrol.
More systematic studies are required to elucidate the effects of resveratrol
on the cell cycle. This applies for short and long term stimulation as well as
studies of cell cycle phase specific apoptosis.
In conclusion, treatment of HL-60 and HepG2 cells with resveratrol for 24 h
causes a complex pattern of effects; low doses cause a slow down in progression
through the cell cycle, while higher doses induces a phase specific cell cycle
arrest.
4.5 Nuclear size and cell granulation
An increase in the size of the cell nucleus was observed in HL-60 but not
HepG2 cells. The increase in nuclear size was primarily observed in the G1
and early S phases of the cell cycle (figure 3.10). An increase in nuclear size
has previously been reported with the HIV protease inhibitors indinavir and
nelfinavir in adipose cells (Caron et al., 2003). To the best of my knowlegde,
no compound has been reported to stimulate nuclear enlargement in leukemia
cells.
One could speculate that the increase in the nuclear size could be due to
changes in the chromatin structure and nuclear laminin content. Modifica-
tions of the chromatin structure by histone acetylation is necessary for gene
transcription (reviewed in Eberharter and Becker, 2002). Though no effect
has been observed of resveratrol on acetylation or deacetylation of histones in
A549 cells (Donnelly et al., 2004), this effect may be cell specific. The observed
effect could also be explained by artefacts risen from incomplete cell lysis by
the detegernt, due the to apoptotic effects of resveratrol. Further studies are
needed to elucidate the effect of resveratrol on the size of cell nuclei in HL-60
cells.
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Resveratrol stimulates an increase in cellular granularity The in-
crease in size of the nucleus is not accompanied by an increase in cell size,
but by an increase in granularity or density of the cells after treatment with
resveratrol for 24 h (figure 3.11). The increase in cell granularity (i.e. alter-
ation of the amount and/or type of cytoplasmic granules) has previously been
reported for ovarian cancer cell lines (Opipari et al., 2004). In concordance, an
increase in mitochondrial mass has been reported in the colon carcinoma cell
line HCT-116 treated with resveratrol (Mahyar-Roemer et al., 2001). These
observations, together with observations presented in this study demonstrate
that resveratrol has a stimulating effect on the amount of cellular organelles.
100 µM resveratrol has previously been shown to stimulate an increase in
cell size in HCT-116 cells after treatment for 24 h (Mahyar-Roemer et al.,
2001). The discrepancy between observations presented in the present study
and the observations made by Mahyar-Roemer et al. (2001) regarding cell size
may be explained by the different cell lines used.
Low concentrations of resveratrol has a significantly greater effect on the
density of treated HL-60 cells than has higher resveratrol concentrations. This
surprising effect is previously unreported, and demonstrates that the effects of
high resveratrol concentration could counteract the effects of lower resveratrol
concentrations.
In conclusion, two previously unreported and surprising observations were
made regarding resveratrol stimulated increase in nucleus size and cell com-
plexity in the present study.
1) The increase in nuclear size is correlated to the phases of the cell cycle.
2) The effects of low concentrations of resveratrol is counteracted by the effect
of higher concentrations
4.6 Apoptosis
Change in nuclear morphology and loss of membrane asymmetry are two hall-
marks of apoptosis, and these were used to study apoptosis stimulating effects
of resveratrol.
Nuclear fragmentation and exposure of PS The study of nuclear con-
densation and fragmentation, and exposure of PS identified a dose dependent
effect of resveratrol (figures 3.12 and 3.14). DAPI staining identified a possi-
ble pro-apoptotic effect of 20 µM resveratrol as seen by nuclear condensation.
However, the same observation could not be made with the Annexin-V binding
assay, though higher doses resulted in a correlation between the results of the
DAPI staining and the Annexin-V binding assay. Both events are controlled
by Caspase-3 activation (Hirata et al., 1998). Thus the difference may be due
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to a sequential process with the loss of membrane asymmetry following the
nuclear condensation and fragmentation.
When treated with resveratrol, HL-60 cells lost membrane integrity as a
function of resveratrol concentration, indicating necrotic death. Depleting cells
of ATP results in necrotic rather than apoptotic cells death (Leist et al., 1997).
Resveratrol has been found to inhibit extracellular ATP synthesis in human
umbilical vein endothelial cells (Arakaki et al., 2003), and to inhibit rat liver
and rat brain mitochondrial F0F1-ATPase activity (Zheng and Ramirez, 1999,
2000). It is therefore possible, that resveratrol stimulates necrotic cell death
though inhibition of ATP synthesis. Interestingly, low levels of resveratrol (4
to 8 µM) inhibited apoptosis stimulated by H2O2 and the anticancer agent
vincristine (Ahmad et al., 2004, 2003).
Activation of Caspase-3 and Caspase-8 Data from Western blot anal-
ysis for cleaved Procaspase-3 were concordant with the dose dependent stim-
ulation of apoptosis. Furthermore, these results were in full agreement with
the Annexin-V assay, where 20 µM resveratrol had no effect on apoptosis in
HL-60 cells. Flow cytometric evaluation of HL-60 cells treated with resvera-
trol revealed that the Caspase-8 activity was stimulated in a dose and time
dependent manner.
Activation of Caspase-8 indicates activation of the extrinsic apoptotic path-
way, and is in concordance with earlier observations (Clement et al., 1998; Su
et al., 2005). However, Pervaiz (2001) observed that 8 to 32 µM resveratrol
stimulates Caspase-9 and Caspase-3 activity, but not Caspase-8 activity in
HL-60 cells. The authors further found that resveratrol stimulated a drop in
the voltage gradient across the mitochondrial membrane as well as stimulated
Cytochrome c release. The observations by Pervaiz (2001) are supported by
similar findings in HL-60 cells by Do¨rrie et al. (2001). The reason for the dis-
crepancy between the activation of the extrinsic pathway by resveratrol found
in the present study and others on one side, and the lack of activation found
by others is unknown.
Cleavage and activation of Caspase-3 in the present study clearly shows
that resveratrol stimulates caspase dependent apoptosis. Caspase-8 activation
occurred later than the other apoptotic markers used in this study. This sug-
gests less activation of the extrinsic pathway compared to the intrinsic path-
way, and thus indicates that Caspase-8 may not be needed for stimulation of
apoptosis. This would be in concordance with observations made by Mahyar-
Roemer et al. (2001). The authors found that Caspase-3 inhibitor, but not
Caspase-8 inhibitor had inhibitory effect on resveratrol stimulated apoptosis
in HCT-116 cells, after treatment for 24 h with 100 µM. Only a single paper
reports a minor effect of resveratrol on apoptosis (Ragione et al., 1998).
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In conclusion, resveratrol stimulates apoptosis in a dose dependent man-
ner. Stimulation of apoptosis involves activation of Caspase-3 and Caspase-8.
Activation of Caspase-8 is a late occurring response, indicating the intrinsic
pathway as the primary pathway for resveratrol stimulated apoptosis. Further-
more, resveratrol may stimulate the necrotic as well as apoptotic cell death.
4.7 Phosphorylation of NF-κB
NF-κB activation in HeLa-pNF-kB-Luc cells Resveratrol is a potent
inhibitor of NF-κB transactivation in unstimulated HeLa-pNF-kB-Luc cells as
well as in cells stimulated with TNF-α (figure 3.18). The inhibitory effect of
resveratrol was 40 fold in stimulated cells compared to 10 fold in unstimulated
cells. For this reason, only stimulated cells were used in evaluation of RelA/p65
phosphorylation.
A dose dependent inhibition of phosphorylated RelA/p65 in TNF-α treated
HeLa-pNF-kB-Luc cells was observed (figure 3.20c). The time span of TNF-α
stimulated RelA/p65 phosphorylation presented in this report is in concor-
dance with earlier reports (Sakurai et al., 2003). Phosphorylation of RelA/p65
may be essential to nuclear translocation (Chen and Greene, 2004; Hu et al.,
2004). The observations presented in this work demonstrate that resveratrol
reduces transcriptional activity of NF-κB, and that the inhibition in stimu-
lated cells correlates to a reduction in RelA/p65 phosphorylation.
RelA/p65 exists predominantly as a 55 kDa fragment in HL-60 cells
Only low levels of unmodified and phosphorylated RelA/p65 were found in
HL-60 cells stimulated with TNF-α (figure 3.19a). Surprisingly, a fragment of
55 kDa was found to bind more antibody compared to the 65 kDa RelA/p65.
The fragment could be a result of unspecific binding of the anti-RelA/p65 an-
tibodies, and the smear observed for unmodified RelA/p65 indeed argues that
this is the case. Less smear was observed with anti-phosphorylated RelA/p65
than with anti-RelA/p65. Treatment of HeLa-pNF-kB-Luc cell lysate with
anti-RelA/p65 resulted in a clear, single protein band and no smear. These
two observations indicate that the observed smear is cell specific and further-
more suggested, that the 55 kDa fragment of the HL-60 cells is a truncated
form of RelA/p65.
Resveratrol does not inhibit RelA/p65 phosphorylation in HL-60
cells HL-60 cells were stimulated with TNF-α and treated with 20 or 80 µM
resveratrol (figure 3.20a). No changes in phosphorylation of RelA/p65 or the
55 kDa fragment of HL-60 cells were observed.
The existence of the truncated RelA/p65 suggests that HL-60 is not a very
good model for studying NF-κB activation. Reports on NF-κB activation
in HL-60 cells by the use of Western blot are sparse, and thus support the
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notion of HL-60 cells being a less useful model for this purpose. One study,
however, verifies the TNF-α stimulated activation of NF-κB in HL-60 (Takada
and Aggarwal, 2004). The authors studied the effect of TNF-α on NF-κB
activity by nuclear extracts and electric mobility shift assay (EMSA). To my
knowledge, the effect of resveratrol on phosphorylation of RelA/p65 has not
previously been studied in HL-60 cells.
In conclusion, resveratrol inhibits immediate TNF-α stimulated RelA/p65
phosphorylation in HeLa-pNF-kB-Luc cells. Furthermore, HL-60 cells may be
a less useful model for studying NF-κB phosphorylation.
4.8 Interference with common cytotoxicity assays
As shown in figures 3.5a and 3.6 the MTT and NR assays caused difficulties
when cells were treated with resveratrol. Both assays were demonstrated to
be reliable in the absence of resveratrol (figure 3.5b and data not shown).
MTT The MTT assay and other variants of tetrazolium salt based assays
have previously been used to study the cytotoxicity of resveratrol on several
cell lines, among these HL-60 cells (Roy et al., 2002) and HepG2 cells (Delmas
et al., 2000).
The results of Hill et al. (1995) and Yoshikawa et al. (1999) were repro-
duced (figure 3.5b), why it is concluded the MTT assay works and produces
valid results. Although the MTT assay has been used to asses cytotoxicity of
resveratrol in HL-60 and HepG2 in previous studies, resveratrol in some way
interfered with the assay in the present work. As a result, the outcome of
the assay is quite unreliable (figure 3.5a). The present observation is in line
with Holian and Walter (2001), who found the MTT cytotoxicity data of cells
treated with resveratrol to be flawed.
Solving the problem regarding the assay was considered beyond the scope
of the present work and was not further explored.
NR Assessing the cytotoxicity of resveratrol was also attempted using the
NR assay. The assay is based on active uptake of the NR dye, and was found
to work very well with cells in adhesion (HepG2) and suspension (HL-60)
cultures (data not shown). The absorption of the dye was furthermore found
to be persistent for at least 2 h (data not shown). These initial results served
to verify the assay in the present study.
When NR was added to a cell suspension of resveratrol treated HL-60 cells,
a rapid (within 30 min) and resveratrol concentration dependent decolouration
occurred. The decolouration correlated to a formation of crystals, indicating
precipitation of the NR dye. This rendered the assay useless.
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To my knowledge, the present study is the first to report this effect of
resveratrol on the NR assay. The effect may be due to changes in pH of
the cultivation medium induced by resveratrol and the dye in conjunction,
resulting in reduced solubility of the dye. However, this was not assessed in
detail.
Because of the resveratrol induced decolouration and crystal formation,
the NR assay was judged unfit to asses the cytotoxicity of resveratrol.
In conclusion, the MTT and NR assays failed to provide support for the ob-
servation made with thymidine incorporation because of interference of resver-
atrol with the assay. This is the first report on the interference by resveratrol
on the NR assay.
4.9 Conclusion
The purpose of this study was to evaluate the effects of resveratrol on DNA
synthesis, cell cycle progression, and apoptosis. The possible role of NF-κB
was also evaluated. It was found that:
• Short incubation times with resveratrol inhibits DNA synthesis in a dose
dependent manner
• The cell cycle is modulated in a complex manner, resulting in accumu-
lation of cells in the S or G1 phases. The phase affected depends on the
concentration of resveratrol
• The apoptosis stimulating effects of resveratrol includes activation of
Caspase-3 and Caspase-8. Activation of the extrinsic pathway is a late
occurring response compared to other apoptosis markers, indicating the
intrinsic pathway as the primary pathway for resveratrol stimulated
apoptosis
• The role of NF-κB in cell cycle modulation and stimulation of apoptosis
remain inconclusive
Additionally, it was found that:
• Resveratrol stimulates an increase in the size of cell nuclei and cell gran-
ularity. The cell size is not affected
• FCS stimulates a reduction in the levels of resveratrol in solution
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